WO2021175284A1 - 检测3种实质性器官肿瘤的探针组合物 - Google Patents

检测3种实质性器官肿瘤的探针组合物 Download PDF

Info

Publication number
WO2021175284A1
WO2021175284A1 PCT/CN2021/079075 CN2021079075W WO2021175284A1 WO 2021175284 A1 WO2021175284 A1 WO 2021175284A1 CN 2021079075 W CN2021079075 W CN 2021079075W WO 2021175284 A1 WO2021175284 A1 WO 2021175284A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
cancer
probe
target region
region shown
Prior art date
Application number
PCT/CN2021/079075
Other languages
English (en)
French (fr)
Inventor
韩晓亮
李永君
吴宁宁
郭媛媛
王建铭
Original Assignee
博尔诚（北京）科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 博尔诚（北京）科技有限公司 filed Critical 博尔诚（北京）科技有限公司
Publication of WO2021175284A1 publication Critical patent/WO2021175284A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Definitions

  • This article relates to a cancer gene methylation detection composition, in particular to a probe composition that specifically recognizes the DNA sequence after Bisulfite treatment, and the detection of lung cancer based on the high-throughput sequencing (NGS) method
  • NGS high-throughput sequencing
  • NGS High-throughput sequencing
  • This technology can simultaneously sequence dozens to millions of DNA molecules, marking the arrival of the post-genome era.
  • different goals such as de novo sequencing and resequencing can be achieved, and the sequence of the genome, transcriptome, and methylome can also be analyzed through different pre-processing.
  • PCR polymerase chain reaction
  • FISH fluorescence in situ hybridization
  • gene chip technology has low price, high sensitivity, simple and fast operation, and high clinical popularity.
  • FISH fluorescence in situ hybridization
  • the gene chip throughput is higher than the former two, and it can detect a large number of genes at the same time.
  • the limitation is that it can only detect known genes or mutations, with low accuracy and high false positives.
  • the NGS technology has the characteristics of high throughput (detecting a large number of known and unknown genes and mutations at the same time), accurate results (higher accuracy than gene chips), fast detection speed, and low cost of detection for each gene. Now Has been gradually applied to clinical disease detection and monitoring and other fields. With the further reduction of sequencing costs in the future, NGS will inevitably gradually replace other high-throughput technologies such as gene chips.
  • target sequence capture and sequencing has become a more mainstream choice.
  • This technology is based on detection requirements, designing capture probes for the genomic region of interest, enriching the target fragment DNA through the principle of hybridization and complementation, and subsequently performing NGS detection.
  • This strategy can be flexibly customized according to the purpose of research or detection, selecting only a small number of gene regions, increasing the depth of sequencing, and effectively discovering the mutation status of the target region, with high sensitivity and accuracy.
  • Liquid biopsy is a method of in vitro diagnosis. It uses non-invasive blood testing to monitor circulating tumor cells (CTC) or circulating tumor DNA (ctDNA) released into the blood by tumors or metastases. This technology can effectively reduce invasiveness. It can realize the sampling of all parts of the tumor and all metastases, overcome tumor heterogeneity (and the current standard tissue biopsy can only reflect the characteristics of a certain part of the tumor), and realize real-time monitoring with higher sensitivity , It is even possible to predict the location of the lesion based on genomic information, which can effectively prolong the survival time of patients. Based on these advantages, liquid biopsy can be used for early diagnosis of tumors, auxiliary staging, prognosis and recurrence monitoring, medication guidance and other aspects. Currently the most commonly used liquid biopsy of free DNA.
  • CtDNA Cell-free DNA
  • cfDNA is a partially degraded endogenous DNA that exists in circulating blood and is free and extracellular. Studies have shown that during the development of tumor tissues, after tumor cells undergo apoptosis, DNA will be released into plasma, and after degradation, free tumor DNA (ctDNA) will be formed.
  • the molecular genetic characteristics of CtDNA (such as gene mutation, microsatellite instability, and tumor suppressor gene promoter methylation, etc.) are consistent with tumor tissue DNA.
  • the collection of peripheral blood is simpler than other clinical detection methods, easy to promote to the grassroots, and because of its non-invasive characteristics, it is easier to be accepted by asymptomatic people. Therefore, the detection of changes in the level of ctDNA methylation in plasma can become one of the important methods for early screening and diagnosis of multiple cancers.
  • Using target sequence capture technology combined with NGS to monitor cfDNA variation and methylation level changes can realize early tumor screening, susceptibility gene monitoring, companion diagnosis, personalized medication, prognostic monitoring and other applications.
  • many companies at home and abroad have launched cancer detection panels of different scales for different application scenarios. Some panels have obtained FDA or CFDA approval numbers.
  • FoundationOne CDx launched by Foundation Medicine covers 324 genes
  • IMPACT launched by Memorial Sloan Kettering Cancer Research Center (MSK) covers 468 cancer-related genes
  • Burning Rock Medicine launched "human EGFR/ALK/BRAF/KRAS gene mutations” Joint detection kit”, “Human EGFR, KRAS, BRAF, PIK3CA, ALK, ROS1 gene mutation detection kit” launched by Nuohe Zhiyuan, etc.
  • Kunyuan Gene also launched the product "Chang Lesi” to detect the methylation level of colorectal cancer in 2018.
  • this article provides a probe composition that can be used for early screening of lung cancer, liver cancer, and pancreatic cancer and other three types of solid organ tumors.
  • the probe composition can: 1) be used in a non-invasive way for early screening of asymptomatic people and prognostic detection of cancer patients, reducing the harm caused by invasive detection, 2) increasing the depth of sequencing and making The breadth of gene detection is better than existing technologies and products, with high throughput, faster detection speed, and low cost of detection for each gene. 3) It can sample all parts of the tumor and all metastases. Overcome tumor heterogeneity, and 4) have higher sensitivity and accuracy, can realize real-time monitoring, and it is even possible to predict the location of lesions through genomic information to effectively prolong the survival of patients.
  • this article involves the following:
  • a probe composition comprising: a probe targeting a specific region of any cancer among lung cancer, liver cancer and pancreatic cancer, wherein the cancer specific region is selected from Seq ID No.: 1-62 Any of them.
  • the probe composition according to item 1 further comprising: a probe targeting a pan-cancer specific region, the pan-cancer specific region selected from any of Seq ID No.: 63-64.
  • the probe composition according to item 3 characterized in that, in the tissue-specific region, Seq ID No.: 65-68 and 71-75 are tissue-specific target regions of the lung.
  • the probe composition according to item 3 characterized in that, in the tissue-specific region, Seq ID No.: 69-70, 76 are tissue-specific target regions of the liver.
  • the probe composition according to item 3 characterized in that, in the tissue-specific region, Seq ID No.: 77-81 is a tissue-specific target region of pancreatic cancer.
  • a hypomethylation probe that hybridizes to the cancer-specific region, pan-cancer-specific region, and tissue-specific region that are converted by bisulfite without CG methylation, and
  • a hypermethylation probe that hybridizes to the cancer-specific region, pan-cancer specific region, and tissue-specific region where the bisulfite-converted CG is fully methylated.
  • hypomethylation probe includes a probe targeting a cancer-specific region Seq ID No.: any of 82-178, targeting Seq ID No. of probes for pan-cancer specific regions: any of 179-180, and Seq ID No. of probes for tissue-specific regions: any of 181-199.
  • a kit comprising the probe composition according to any one of items 1-11.
  • This article also provides a method for detecting tumors in three solid organs, including lung cancer, liver cancer, and pancreatic cancer, using the probe composition.
  • This article also provides a method for simultaneously detecting changes in the methylation level of the above three cancers by using the kit.
  • Liquid biopsy is a non-invasive tumor detection, which can be applied to asymptomatic and patient groups who cannot obtain tissue samples.
  • the average sequencing depth exceeds 5000X.
  • the screening of all high-incidence cancers can be completed at one time, which improves the detection efficiency.
  • the average price of each marker is lower than the existing single-marker detection in the market.
  • one Panel can complete the screening of major cancers, which saves the cost of probe synthesis, simplifies the experimental process, and facilitates the operation of experimenters.
  • FIG 1 shows the implementation process of this article
  • This article provides a probe composition for cancer gene methylation detection.
  • NGS high-throughput sequencing
  • the probe is a single-stranded or double-stranded DNA with a length of tens to hundreds or even thousands of base pairs, which can take advantage of molecular denaturation, renaturation and high accuracy of base complementary pairing, and can be complementary to the sample to be tested
  • the unlabeled single-stranded DNA or RNA is hydrogen-bonded (hybridized) to form a double-stranded complex (hybrid).
  • detection systems such as autoradiography or enzyme-linked reaction can be used to detect the results of the hybridization reaction.
  • the region that complementarily binds or hybridizes with the probe is the specific target region. Multiple probes are combined into a probe composition.
  • a cancer-specific region refers to a significant difference in the methylation level of this region compared with normal control tissues in a small number of cancer types.
  • pan-cancer specific region refers to a significant difference in the methylation level of this region compared with normal control tissues in most cancer types.
  • Tissue-specific region refers to the significant difference in the methylation level of the region in a specific tissue compared with other tissues.
  • DNA methylation refers to the methylation process that occurs at the 5th carbon atom of cytosine in CpG dinucleotides. As a stable modification state, DNA methyltransferase can follow DNA The duplication process of dna is inherited to the new generation DNA, which is an important epigenetic mechanism. When DNA is methylated, the methylation of the gene promoter region can lead to the silence of tumor suppressor gene transcription, so it is related to the occurrence of tumors. close. Abnormal methylation includes hypermethylation of tumor suppressor genes and DNA repair genes, hypomethylation of repetitive sequence DNA, and loss of imprinting of certain genes, which are related to the occurrence of a variety of tumors.
  • Panel refers to the probe composition used in this article.
  • a probe composition includes: a probe targeting a specific region of any cancer among lung cancer, liver cancer and pancreatic cancer, wherein the cancer specific region is selected from Seq ID No.: any of 1-62; a probe targeting a pan-cancer specific region selected from Seq ID No.: any of 63-64; and targeting a tissue-specific region
  • the probe, the tissue-specific region is selected from any of Seq ID No.: 65-81.
  • Seq ID No.: 65-68 and 71-75 are tissue-specific target regions of the lung.
  • a probe composition includes: a probe targeting a specific region of any cancer among lung cancer, liver cancer and pancreatic cancer, wherein the cancer specific region is selected from Seq ID No.: any of 1-62; a probe targeting a pan-cancer specific region selected from Seq ID No.: any of 63-64; and targeting a tissue-specific region
  • the probe, the tissue-specific region is selected from any of Seq ID No.: 65-81.
  • Seq ID No.: 69-70 and 76 are tissue-specific target regions of the liver.
  • a probe composition includes: a probe targeting a specific region of any cancer among lung cancer, liver cancer and pancreatic cancer, wherein the cancer specific region is selected from Seq ID No.: any of 1-62; a probe targeting a pan-cancer specific region selected from Seq ID No.: any of 63-64; and targeting a tissue-specific region
  • the probe, the tissue-specific region is selected from any of Seq ID No.: 65-81.
  • Seq ID No.: 77-81 are tissue-specific target regions for pancreatic cancer.
  • the above-mentioned probe composition includes a hypomethylation probe, which is different from the cancer-specific region and pan-cancer-specific region converted by bisulfite without CG methylation.
  • the hypomethylation probes include probes targeting cancer-specific regions Seq ID No.: any of 82-178, and probes targeting pan-cancer specific regions Seq ID No.: 179-180 Any, and the probe Seq ID No. that targets tissue-specific regions: Any of 181-199.
  • the hypermethylation probes include probes targeting cancer-specific regions, Seq ID No.: any of 200-296, and probes targeting pan-cancer specific regions, Seq ID No.: 297-298, Seq ID No.: any of 299-317 probes targeting tissue-specific regions.
  • Seq ID No. 82, Seq ID No. 83, and Seq ID No. 84 are all hypomethylated probes that target the target region shown in Seq ID No. 1, Seq ID No. 200 , Seq ID No. 201 and Seq ID No. 202 are hypermethylated probes that target the target region shown in Seq ID No. 1.
  • Seq ID No. 85 and Seq ID No. 86 are both hypomethylated probes that target the target region shown in Seq ID No. 2, and Seq ID No. 203 and Seq ID No. 204 are both targeted to Seq ID No. .2 Hypermethylated probes in the target region shown.
  • Seq ID No. 89 is a hypomethylated probe that targets the target region shown in Seq ID No. 4
  • Seq ID No. 207 is a hypermethylated probe that targets the target region shown in Seq ID No. 4.
  • Seq ID No. 90 and Seq ID No. 91 are hypomethylated probes that target the target region shown in Seq ID No. 5, and Seq ID No. 208 and Seq ID No. 209 are both targeted to Seq ID No. .3 Hypermethylated probes in the target region shown.
  • Seq ID No. 89 is a hypomethylated probe that targets the target region shown in Seq ID No. 4
  • Seq ID No. 207 is a hypermethylated probe that targets the target region shown in Seq ID No. 4.
  • Seq ID No. 90 and Seq ID No. 91 are hypomethylated probes that target the target region shown in Seq ID No. 5, and Seq ID No. 208 and Seq ID No. 209 are both targeted to Seq ID No. .3 Hypermethylated
  • Seq ID No. 92 is a hypomethylated probe targeting the target region shown in Seq ID No. 6, and Seq ID No. 210 is a hypermethylated probe targeting the target region shown in Seq ID No. 6.
  • Seq ID No. 93 is a hypomethylated probe targeting the target region shown in Seq ID No. 7, and Seq ID No. 211 is a hypermethylated probe targeting the target region shown in Seq ID No. 7.
  • Seq ID No. 94 and Seq ID No. 95 are both hypomethylated probes that target the target region shown in Seq ID No. 8, and Seq ID No. 212 and Seq ID No. 213 are both targeted to Seq ID No.
  • Seq ID No. 97, and Seq ID No. 98 are all hypomethylated probes that target the target region shown in Seq ID No. 9, Seq ID No. 214, Seq ID No. 215 and Seq ID No. 215.
  • Seq ID No. 216 are all hypermethylated probes that target the target region shown in Seq ID No. 9.
  • Seq ID No. 99 is a hypomethylated probe that targets the target region shown in Seq ID No. 10
  • Seq ID No. 217 is a hypermethylated probe that targets the target region shown in Seq ID No. 10.
  • Seq ID No. 100 is a hypomethylated probe that targets the target region shown in Seq ID No. 11, and Seq ID No. 218 is a hypermethylated probe that targets the target region shown in Seq ID No. 11.
  • Seq ID No. 101 is a hypomethylated probe targeting the target region shown in Seq ID No. 12, and Seq ID No. 219 is a hypermethylated probe targeting the target region shown in Seq ID No. 12.
  • Seq ID No. 102 is a hypomethylated probe that targets the target region shown in Seq ID No. 13, and Seq ID No. 220 is a hypermethylated probe that targets the target region shown in Seq ID No. 13.
  • Seq ID No. 103 and Seq ID No. 104 are both hypomethylated probes that target the target region shown in Seq ID No. 14, and Seq ID No. 221 and Seq ID No. 222 are both targeted to Seq ID No.
  • Seq ID No. 106 are both hypomethylated probes that target the target region shown in Seq ID No. 15, and Seq ID No. 223 and Seq ID No. 224 are both targeted to Seq ID No.
  • Seq ID No. 107 and Seq ID No. 108 are hypomethylated probes that target the target region shown in Seq ID No. 16, and Seq ID No. 225 and Seq ID No. 226 are both targeted to Seq ID No.
  • Seq ID No. 109 and Seq ID No. 110 are hypomethylated probes that target the target region shown in Seq ID No. 17, and Seq ID No. 227 and Seq ID No.
  • Seq ID No. 111 is a hypomethylated probe targeting the target region shown in Seq ID No. 18, and Seq ID No. 229 is a hypermethylated probe targeting the target region shown in Seq ID No. 18.
  • Seq ID No. 112 and Seq ID No. 113 are both hypomethylated probes that target the target region shown in Seq ID No. 19, and Seq ID No. 230 and Seq ID No. 231 are both targeted to Seq ID No.
  • Seq ID No. 114 is a hypomethylated probe targeting the target region shown in Seq ID No. 20, and Seq ID No.
  • Seq ID No. 232 is a hypermethylated probe targeting the target region shown in Seq ID No. 20.
  • Seq ID No. 115 is a hypomethylated probe targeting the target region shown in Seq ID No. 21, and Seq ID No. 233 is a hypermethylated probe targeting the target region shown in Seq ID No. 21.
  • Seq ID No. 116 is a hypomethylated probe targeting the target region shown in Seq ID No. 22, and Seq ID No. 234 is a hypermethylated probe targeting the target region shown in Seq ID No. 22.
  • Seq ID No. 117, Seq ID No. 118, and Seq ID No. 119 are all hypomethylated probes that target the target region shown in Seq ID No. 23, Seq ID No. 235, Seq ID No.
  • Seq ID No. 237 is a hypermethylated probe that targets the target region shown in Seq ID No. 23.
  • Seq ID No. 120 and Seq ID No. 121 are both hypomethylated probes that target the target region shown in Seq ID No. 24, and Seq ID No. 238 and Seq ID No. 239 are both targeted to Seq ID No.
  • Seq ID No. 124 and Seq ID No. 125 are hypomethylated probes that target the target region shown in Seq ID No. 26, and Seq ID No. 242 and Seq ID No. 243 are both targeted to Seq ID No.
  • Seq ID No. 126 is a hypomethylated probe that targets the target region shown in Seq ID No. 27, and Seq ID No. 244 is a hypermethylated probe that targets the target region shown in Seq ID No. 27.
  • Seq ID No. 127 and Seq ID No. 128 are both hypomethylated probes that target the target region shown in Seq ID No. 28, and Seq ID No. 245 and Seq ID No. 246 are both targeted to Seq ID No.
  • the hypermethylated probe in the target region shown in .28. Seq ID No. 129 and Seq ID No. 130 are hypomethylation probes that target the target region shown in Seq ID No. 29, and Seq ID No. 247 and Seq ID No. 248 are both targeted to Seq ID No.
  • Seq ID No. 131 is a hypomethylated probe targeting the target region shown in Seq ID No. 30, and Seq ID No. 249 is a hypermethylated probe targeting the target region shown in Seq ID No. 30.
  • Seq ID No. 132 and Seq ID No. 133 are both hypomethylated probes that target the target region shown in Seq ID No. 31, and Seq ID No. 250 and Seq ID No.
  • Seq ID No. 251 are both targeted to Seq ID No.
  • Seq ID No. 134 is a hypomethylated probe targeting the target region shown in Seq ID No. 32
  • Seq ID No. 252 is a hypermethylated probe targeting the target region shown in Seq ID No. 32.
  • Seq ID No. 135 and Seq ID No. 136 are hypomethylated probes that target the target region shown in Seq ID No. 33
  • Seq ID No. 253 and Seq ID No. 254 are both targeted to Seq ID No.
  • Seq ID No. 137 is a hypomethylated probe targeting the target region shown in Seq ID No. 34, and Seq ID No.
  • Seq ID No. 255 is a hypermethylated probe targeting the target region shown in Seq ID No. 34.
  • Seq ID No. 138 and Seq ID No. 139 are both hypomethylated probes that target the target region shown in Seq ID No. 35, and Seq ID No. 256 and Seq ID No. 257 are both targeted to Seq ID No.
  • Seq ID No. 140 is a hypomethylated probe targeting the target region shown in Seq ID No. 36, and Seq ID No. 258 is a hypermethylated probe targeting the target region shown in Seq ID No. 36.
  • Seq ID No. 141 and Seq ID No. 142 are hypomethylated probes that target the target region shown in Seq ID No.
  • Seq ID No. 146 and Seq ID No. 146 are both targeted to Seq ID No.
  • Seq ID No. 143 and Seq ID No. 144 are hypomethylated probes that target the target region shown in Seq ID No. 38
  • Seq ID No. 261 and Seq ID No. 262 are both targeted to Seq ID No.
  • Seq ID No. 145 is a hypomethylated probe that targets the target region shown in Seq ID No. 39
  • Seq ID No. 263 is a hypermethylated probe that targets the target region shown in Seq ID No. 39.
  • Seq ID No. 147 are hypomethylated probes that target the target region shown in Seq ID No. 40, and Seq ID No. 264 and Seq ID No. 265 are both targeted to Seq ID No.
  • Seq ID No. 148 is a hypomethylated probe targeting the target region shown in Seq ID No. 41
  • Seq ID No. 266 is a hypermethylated probe targeting the target region shown in Seq ID No. 41.
  • Seq ID No.149 is a hypomethylated probe targeting the target region shown in Seq ID No.42
  • Seq ID No.267 is a hypermethylated probe targeting the target region shown in Seq ID No.42.
  • Seq ID No. 150 is a hypomethylated probe targeting the target region shown in Seq ID No. 43
  • Seq ID No. 268 is a hypermethylated probe targeting the target region shown in Seq ID No. 43.
  • Seq ID No. 151 is a hypomethylated probe targeting the target region shown in Seq ID No. 44
  • Seq ID No. 269 is a hypermethylated probe targeting the target region shown in Seq ID No. 44.
  • Seq ID No. 152 and Seq ID No. 153 are hypomethylated probes that target the target region shown in Seq ID No. 45
  • Seq ID No. 270 and Seq ID No. 271 are both targeted to Seq ID No.
  • Seq ID No. 154 is a hypomethylated probe targeting the target region shown in Seq ID No. 46
  • Seq ID No. 272 is a hypermethylated probe targeting the target region shown in Seq ID No. 46.
  • Seq ID No. 155 is a hypomethylated probe targeting the target region shown in Seq ID No. 47
  • Seq ID No. 273 is a hypermethylated probe targeting the target region shown in Seq ID No. 47.
  • Seq ID No.156 is a hypomethylated probe targeting the target region shown in Seq ID No.48
  • Seq ID No.274 is a hypermethylated probe targeting the target region shown in Seq ID No.48.
  • Seq ID No. 157 is a hypomethylated probe targeting the target region shown in Seq ID No. 49, and Seq ID No.
  • Seq ID No. 275 is a hypermethylated probe targeting the target region shown in Seq ID No. 49.
  • Seq ID No.158 is a hypomethylated probe targeting the target region shown in Seq ID No.50
  • Seq ID No.276 is a hypermethylated probe targeting the target region shown in Seq ID No.50.
  • Seq ID No. 159 and Seq ID No. 160 are both hypomethylated probes that target the target region shown in Seq ID No. 51, and Seq ID No. 277 and Seq ID No. 278 are both targeted to Seq ID No.
  • Seq ID No. 161 is a hypomethylated probe targeting the target region shown in Seq ID No. 52, and Seq ID No.
  • Seq ID No. 279 is a hypermethylated probe targeting the target region shown in Seq ID No. 52.
  • Seq ID No. 162 and Seq ID No. 163 are both hypomethylated probes that target the target region shown in Seq ID No. 53, and Seq ID No. 280 and Seq ID No. 281 are both targeted to Seq ID No.
  • Seq ID No.164 is a hypomethylated probe targeting the target region shown in Seq ID No.54
  • Seq ID No.282 is a hypermethylated probe targeting the target region shown in Seq ID No.54.
  • Seq ID No. 165 and Seq ID No. 166 are both hypomethylated probes that target the target region shown in Seq ID No.
  • Seq ID No. 167 and Seq ID No. 168 are both hypomethylated probes that target the target region shown in Seq ID No. 56, and Seq ID No. 285 and Seq ID No. 286 are both targeted to Seq ID No.
  • Seq ID No. 169 and Seq ID No. 170 are both hypomethylated probes that target the target region shown in Seq ID No. 57, and Seq ID No. 287 and Seq ID No. 288 are both targeted to Seq ID No.
  • Seq ID No. 171 and Seq ID No. 172 are both hypomethylated probes that target the target region shown in Seq ID No. 58, and Seq ID No. 289 and Seq ID No. 290 are both targeted to Seq ID No.
  • Seq ID No. 173 and Seq ID No. 174 are both hypomethylated probes that target the target region shown in Seq ID No. 59, and Seq ID No. 291 and Seq ID No. 292 are both targeted to Seq ID No.
  • Seq ID No.175 is a hypomethylated probe targeting the target region shown in Seq ID No.60
  • Seq ID No.293 is a hypermethylated probe targeting the target region shown in Seq ID No.60.
  • Seq ID No. 176 and Seq ID No. 177 are both hypomethylated probes that target the target region shown in Seq ID No. 61, and Seq ID No. 294 and Seq ID No. 295 are both targeted to Seq ID No.
  • Seq ID No. 178 is a hypomethylated probe targeting the target region shown in Seq ID No. 62
  • Seq ID No. 296 is a hypermethylated probe targeting the target region shown in Seq ID No. 62.
  • Seq ID No. 179 is a hypomethylated probe targeting the target region shown in Seq ID No. 63
  • Seq ID No. 297 is a hypermethylated probe targeting the target region shown in Seq ID No. 63.
  • Seq ID No. 180 is a hypomethylated probe targeting the target region shown in Seq ID No. 64
  • Seq ID No. 298 is a hypermethylated probe targeting the target region shown in Seq ID No. 64.
  • Seq ID No. 181 is a hypomethylated probe targeting the target region shown in Seq ID No. 65
  • Seq ID No. 299 is a hypermethylated probe targeting the target region shown in Seq ID No. 65.
  • Seq ID No. 182 is a hypomethylated probe targeting the target region shown in Seq ID No.
  • Seq ID No. 66 is a hypermethylated probe targeting the target region shown in Seq ID No. 66.
  • Seq ID No. 183 is a hypomethylated probe that targets the target region shown in Seq ID No. 67
  • Seq ID No. 301 is a hypermethylated probe that targets the target region shown in Seq ID No. 67.
  • Seq ID No. 184 is a hypomethylated probe targeting the target region shown in Seq ID No. 68
  • Seq ID No. 302 is a hypermethylated probe targeting the target region shown in Seq ID No. 68.
  • Seq ID No. 185 is a hypomethylated probe that targets the target region shown in Seq ID No. 69, and Seq ID No.
  • Seq ID No. 303 is a hypermethylated probe that targets the target region shown in Seq ID No. 69.
  • Seq ID No. 186 is a hypomethylated probe targeting the target region shown in Seq ID No. 70
  • Seq ID No. 304 is a hypermethylated probe targeting the target region shown in Seq ID No. 70.
  • Seq ID No. 187 and Seq ID No. 188 are hypomethylated probes that target the target region shown in Seq ID No. 71, and Seq ID No. 305 and Seq ID No. 306 are both targeted to Seq ID No.
  • Seq ID No. 189 is a hypomethylated probe targeting the target region shown in Seq ID No. 72, and Seq ID No.
  • Seq ID No. 307 is a hypermethylated probe targeting the target region shown in Seq ID No. 72.
  • Seq ID No. 190 is a hypomethylated probe targeting the target region shown in Seq ID No. 73
  • Seq ID No. 308 is a hypermethylated probe targeting the target region shown in Seq ID No. 73.
  • Seq ID No. 191 is a hypomethylated probe targeting the target region shown in Seq ID No. 74
  • Seq ID No. 309 is a hypermethylated probe targeting the target region shown in Seq ID No. 74.
  • Seq ID No. 192 is a hypomethylated probe that targets the target region shown in Seq ID No. 75
  • Seq ID No. 310 is a hypermethylated probe that targets the target region shown in Seq ID No.
  • Seq ID No. 193 is a hypomethylated probe that targets the target region shown in Seq ID No. 76
  • Seq ID No. 311 is a hypermethylated probe that targets the target region shown in Seq ID No. 76.
  • Seq ID No. 194 is a hypomethylated probe targeting the target region shown in Seq ID No. 77
  • Seq ID No. 312 is a hypermethylated probe targeting the target region shown in Seq ID No. 77.
  • Seq ID No. 195 is a hypomethylated probe targeting the target region shown in Seq ID No. 78
  • Seq ID No. 313 is a hypermethylated probe targeting the target region shown in Seq ID No. 78.
  • Seq ID No. 196 is a hypomethylated probe targeting the target region shown in Seq ID No. 79
  • Seq ID No. 314 is a hypermethylated probe targeting the target region shown in Seq ID No. 79.
  • Seq ID No. 197 and Seq ID No. 198 are hypomethylated probes that target the target region shown in Seq ID No. 80, and Seq ID No. 315 and Seq ID No. 316 are both targeted to Seq ID No. A hypermethylated probe in the target region shown in .80.
  • Seq ID No.199 is a hypomethylated probe targeting the target region shown in Seq ID No.81
  • Seq ID No.317 is a hypermethylated probe targeting the target region shown in Seq ID No.81. Table 1 shows the target sequence targeted by the probe.
  • the length of each probe in the above-mentioned probe composition is 40-60 bp, preferably 45-56 bp, preferably 50-56 bp, and more preferably 50 bp.
  • This article also provides a kit.
  • the kit includes the probe composition according to any one of the above embodiments.
  • the above-mentioned probe composition is used to prepare a kit for detecting lung cancer, liver cancer and pancreatic cancer.
  • This article also provides a chip.
  • the probe composition according to any one of the above embodiments is immobilized on the chip.
  • This article also provides a method for detecting tumors in three solid organs, including lung cancer, liver cancer, and pancreatic cancer, using the probe composition.
  • the detection method uses hybrid capture to enrich cfDNA, and uses NGS technology to detect methylation sites that are highly related to cancer. Covers the three solid organ malignancies (lung cancer, liver cancer and pancreatic cancer) with the highest incidence in my country. Finally, based on the detection of gene methylation changes in plasma cfDNA, it provides information for early screening and early diagnosis of multiple cancers.
  • This application also provides a method for simultaneously detecting changes in the methylation level of the above three cancers by using the kit.
  • this application relates to three in vitro cancer detection methods for subjects, including the following steps: collecting a sample of the subject; extracting and purifying the DNA in the sample; constructing a DNA library for sequencing based on the purified DNA sample; Bisulfite transforms the constructed DNA library; pre-PCR amplifies the bisulfite-converted DNA library; uses the probe composition to hybridize and capture the sample amplified by pre-PCR; Products captured by hybridization; perform high-throughput next-generation sequencing on the products amplified by PCR and captured by hybridization; analyze the sequencing data to determine the methylation level of the sample; judge based on the methylation level of the sample The condition of the patient.
  • the subject is suspected of having cancer.
  • the sample collected from the subject is a plasma sample.
  • the conversion is treatment with bisulfite.
  • the probe composition includes: 2 probes targeting a pan-cancer specific region, n probes targeting a cancer-specific region, and m probes targeting a tissue-specific region.
  • the probe composition includes: a hypomethylation probe that hybridizes to the cancer-specific region, pan-cancer specific region, and tissue-specific region that are converted by bisulfite and do not contain CG methylation , And a hypermethylation probe that hybridizes to the cancer-specific region, pan-cancer-specific region, and tissue-specific region where the bisulfite-converted CG is fully methylated.
  • the length of each probe in the probe composition is 40-60 bp.
  • the length of each probe in the probe composition is 45-56 bp, preferably 50-56 bp, and more preferably 50 bp.
  • the n probes in the probe composition target a cancer-specific region, where n is any integer selected from 1-192; wherein, the cancer-specific region is selected from Seq ID No.: Any of 1-62.
  • the m probes in the probe composition target the tissue-specific region, where m is an integer selected from 1-116; wherein, the tissue-specific region is selected from Seq ID No. : Any of 65-81.
  • the hypomethylation probes include probes targeting cancer-specific regions Seq ID No.: any of 82-178, and probes targeting pan-cancer specific regions Seq ID No.: 179-180 Any, and the probe Seq ID No. that targets tissue-specific regions: Any of 181-199.
  • the hypermethylation probes include probes targeting cancer-specific regions, Seq ID No.: any of 200-296, and probes targeting pan-cancer specific regions, Seq ID No.: 297-298, Seq ID No.: any of 299-317 probes targeting tissue-specific regions.
  • the interpretation includes the following steps: (1) compare the pan-cancer specific region database and perform interpretation to confirm whether the subject has cancer; (2) compare the cancer specific region database and perform interpretation To confirm that the subject's cancer is one of several suspected cancers; (3) Compare the tissue-specific area database and perform interpretation to confirm the subject's cancer site.
  • the step (1) includes the following interpretation: judging whether the methylation level of the pan-cancer specific region Seq ID No.: 63 is greater than or equal to 55%, and the pan-cancer specific region Seq ID No.: 64 If the methylation level of is greater than or equal to 60%, it is judged that the patient has cancer.
  • the step (2) includes the following interpretation: if among the n probes targeting the cancer-specific region, the methylation level of the region targeted by n1 probes is greater than or equal to the respective threshold, and n1/n ⁇ 20%, preferably n1/n ⁇ 30%, then it is judged that the patient has any one of the tissue-specific cancers.
  • the step (3) includes the following interpretation: among the m probes targeting the tissue-specific region, the methylation level of the region targeted by m1 probes is greater than or equal to the respective threshold, and then further analysis is greater than or equal to the respective threshold.
  • Threshold m1 probes target tissues and count the number of probes in each tissue that are greater than or equal to the threshold, and judge that the tissue in which the patient suffers from cancer is the tissue with the largest number of probes with methylation level greater than or equal to the threshold. Table 1 below also shows the methylation threshold of each target region.
  • Agilent 2100 performs fragment detection, and Qubit is directly used in subsequent experiments.
  • DNA protection buffer added to the liquid turns blue. Mix gently by pipetting, and then divide into two tubes on the PCR machine.
  • the number of PCR cycles is adjusted according to the amount of DNA input.
  • the reference data is as follows:
  • the length of the library is about 270bp-320bp.
  • Component volume Pre-amplified product 750ng corresponding volume Hyb human blocker 5 ⁇ l Junction blocker 6 ⁇ l Enhancer 5 ⁇ l
  • Hyb buffer solution at room temperature to melt, there will be precipitation after melting, and place it in a 65°C water bath to preheat it after mixing. After completely dissolved (no precipitation and turbidity), take 20 ⁇ l Hyb buffer solution and place In the new 200 ⁇ l PCR tube, close the tube cap, mark it as A, and continue to incubate it in a 65°C water bath for later use.
  • Methylation bio-information analysis process It is roughly as follows: Use quality control software such as trimmomatic to check the quality of sequencing, remove low-quality reads, and then use comparison software such as Bismarker to compare the clean data after quality control to the reference genome, and use R packages such as methykit to extract the corresponding Methylation site. Finally, calculate the methylation ratio of each target area on the Panel.
  • quality control software such as trimmomatic to check the quality of sequencing, remove low-quality reads
  • comparison software such as Bismarker to compare the clean data after quality control to the reference genome
  • R packages such as methykit
  • a lung cancer sample was detected by the Panel of this application, and peripheral blood was collected according to the method in Example 1; the database was constructed and sequenced on the Illumina platform; the sequencing data was subjected to the above-mentioned biological information analysis process to obtain the methylation level.
  • the results are shown in Table 19 As shown (Table 19 shows the detected target regions greater than or equal to the methylation threshold).
  • Seq ID No. 68 Seq ID No. 71, Seq ID No. 72, and Seq ID No. 73 is greater than or equal to the respective threshold of methylation level, and no other tissue-specific markers have methylation greater than or equal to their respective thresholds. Therefore, among tissue-specific markers greater than or equal to their respective methylation thresholds, The lung tissue-specific markers are the most, and the sample is finally judged to be a sample with lung cancer.
  • a liver cancer sample was detected by the Panel of this application, and peripheral blood was collected according to the method of Example 1; the database was constructed and sequenced on the Illumina platform; the sequencing data was subjected to the above-mentioned biological information analysis process to obtain the methylation level.
  • Table 20 shows the detected target regions greater than or equal to the methylation threshold).
  • liver tissue-specific markers are the most, and the sample is finally judged to be a sample with liver cancer .
  • pancreatic cancer was detected by the Panel of this application, and peripheral blood was collected according to the method in Example 1; the database was constructed and sequenced on the Illumina platform; the sequencing data was subjected to the above-mentioned biological information analysis process to obtain the methylation level.
  • the results are as follows 21 (Table 21 shows the detected target regions greater than or equal to the methylation threshold).
  • pan-cancer specific markers TBX15 and CRYGD genes greater than or equal to 55% and 60%, and then preliminarily determine that the sample is a sample with cancer; secondly, determine and read
  • the methylation levels of the cancer-specific markers HOPX, SFRP2, GFRA1, HOXB4, and SALL1 are greater than or equal to the respective thresholds shown in Table 1 (as shown in Table 21 above), and the sample is further judged to have the following 11 cancers ( Esophageal cancer, gastric cancer, colorectal cancer, lung cancer, liver cancer, pancreatic cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer and endometrial cancer) samples of any cancer; finally, the interpretation of tissue-specific markers, based on In Table 21, the target regions that are greater than or equal to their respective thresholds, it can be seen that there are 5 target regions that are specific to pancreatic tissue Seq ID No.
  • Seq ID No. 78 Seq ID No. 79, Seq ID No. 80, and Seq ID No.81 is greater than or equal to the respective threshold of methylation level, and no other tissue-specific markers have methylation greater than or equal to their respective thresholds. Therefore, among tissue-specific markers greater than or equal to their respective methylation thresholds, The pancreatic tissue-specific markers are the most, and the sample is finally judged to be a sample with pancreatic cancer.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

公开了一种探针组合物。该探针组合物通过对TCGA数据库以及GEO数据库的甲基化数据荟萃分析，筛选出3.75Kbp的捕获区域，包括多达36个与癌症高度相关的甲基化变化基因与非编码DNA区域。利用该探针组合物可以一次性检测肺癌、肝癌和胰腺癌3种实质性器官肿瘤的甲基化水平改变，可用于无症状人群的早期筛查，以及癌症患者的预后检测。

Description

一种检测3种实质性器官肿瘤的探针组合物 技术领域
本文涉及一种癌症基因甲基化检测组合物，特别涉及一种特异性识别重亚硫酸盐(Bisulfite)处理后的DNA序列的探针组合物，以及基于高通量测序(NGS)方法检测肺癌、肝癌和胰腺癌等3种实质性器官肿瘤游离DNA甲基化水平变化的应用。
背景技术
高通量测序(NGS)技术是现代基因组学研究领域革命性的创新，该技术可以同时对几十到几百万条DNA分子进行序列分析，这标志着后基因组时代的到来。通过对测序深度的控制，可实现从头测序和重测序等不同的目标，也可以通过不同的前期处理，分析基因组、转录组和甲基化组的序列。
目前临床基因检测的技术主要是聚合酶链式反应(PCR)、荧光原位杂交(FISH)和基因芯片技术。PCR仪器设备价格低，灵敏性高，操作简单快速，在临床的普及度高，但是受技术限制，只能同时检测少数几个基因。FISH灵敏度高，但操作难度较大。基因芯片通量高于前两者，可以同时检测大量的基因。但局限在于只能检测已知的基因或变异，准确性低，假阳性高。而NGS技术具有通量高(同时检测大量已知和未知的基因及变异)，结果准确(准确率高于基因芯片)，检测速度较快，均摊到每个基因的检测成本低等特点，现在已经逐渐应用到临床疾病检测和监控等领域。随着未来测序费用的进一步降低，NGS必然会逐步取代基因芯片等其他高通量技术。
由于目前常规全基因组测序的总价比较高，如果为了检测稀有变异而增加测序深度，则最终价格让消费者难以承受。因此目标序列捕获测序成为比较主流的选择，该技术是根据检测的需求，针对感兴趣的基因组区域设计捕获探针，通过杂交互补的原理富集目标片段DNA，并在后续进行NGS检测。这种策略可以根据研究或检测的目的进行灵活定制，只选择少量的基因区域，加大测序深度，可以有效的发现目标区域变异的状况，具有很高的灵敏 度和准确性。
在癌症的发生和进展过程中，遗传信息会产生一系列的变化，包括DNA的突变、插入/缺失，染色体结构变异，拷贝数变异，以及表观遗传信息的改变。在癌症的演进过程中，DNA序列的变异是随机发生的，仅当变异发生在关键的生长控制基因时，才可以导致恶性肿瘤的产生。而大多数的基因表达异常是源于表观遗传的改变，通常是DNA甲基化水平的改变。研究表明，基因甲基化水平的改变早于基因变异，跟踪检测基因甲基化的变化，可以较早的预测癌症产生。近年来，随着基因组学的发展，现在已经对超过30种癌症的表观基因组进行了研究。结果显示，尽管DNA甲基化并非在每种癌中都占主导地位，但毫无疑问的是，基因甲基化修饰模式的变化会改变细胞的发展倾向以及肿瘤的表型，从而对大多数癌症的发生发展起重要的影响。
2018年初癌症基因组图谱(TCGA)发表了27篇总结性的分析文章，对历时十多年的30多种癌症数据做了迄今为止最全面的泛癌基因组分析。在通过整合染色体变异、DNA甲基化、RNA和蛋白等多种数据进行分析后，发现，解剖学上的33中癌症可以根据分子特征分成28个亚型。在某种分子亚型会包括25种传统意义上的癌症。这个结果说明，来源于不同器官的癌症存在共同的分子特征。与此同时，来源于同一器官的癌症可能有不同的基因组图谱。由此可见，在不远的将来，癌症筛查和诊断标志物的开发必将引入更多泛癌的概念，不仅研究解剖学层次的癌症，更应在分子水平研究癌症，开发出可以覆盖某种分子分型的泛癌标志物。
液体活检是体外诊断的一种方式，采用非侵入性的血液检测，可以监测肿瘤或转移灶释放到血液的循环肿瘤细胞(CTC)或循环肿瘤DNA(ctDNA)，该技术可以有效降低侵入性造成的危害，且能够实现对肿瘤各部分和所有转移灶的采样，克服肿瘤异质性(而目前采用的标准组织活检只能反映肿瘤某一部分的特征)，并实现实时监测，具有更高的灵敏度，甚至有可能通过基因组信息预测发生病变的部位，可以有效延长患者生存期。根据这些优点，液体活检可以用于肿瘤的早诊、辅助分期、预后和复发监测，用药指导等方面。目前最常用于的液体活检的游离DNA。
游离DNA(cfDNA)是存在于循环血中游离与细胞外的部分降解的内源性DNA。研究表明，肿瘤组织在发生发展的过程中，其肿瘤细胞凋亡后， 会向血浆中释放DNA，经降解后，形成游离肿瘤DNA(ctDNA)。CtDNA的分子遗传特征(如基因突变，微卫星不稳定性和抑癌基因启动子甲基化等)与肿瘤组织DNA相一致。在多癌的早期筛查和检测中，采集外周血比其它临床检测手段更为简便、易于向基层推广，而且由于其无创的特点，更易于被无症状人群接受。因此通过检测血浆中的ctDNA甲基化水平改变，可以成为多癌早期筛查和诊断的重要手段之一。
利用目标序列捕获技术结合NGS监测cfDNA的变异以及甲基化水平变化，可以实现肿瘤早期筛查、易感基因监测、伴随诊断、个性化用药、预后监测等各方面的应用。目前国内外多个公司都推出了不同规模，针对不同应用场景的癌症检测panel，有部分panel已经获得了FDA或CFDA的批准文号。如Foundation Medicine推出的FoundationOne CDx覆盖324个基因，纪念斯隆·凯特琳癌症研究中心(MSK)推出的IMPACT覆盖468种癌症相关基因，燃石医学推出的“人EGFR/ALK/BRAF/KRAS基因突变联合检测试剂盒”，诺禾致源推出的“人EGFR、KRAS、BRAF、PIK3CA、ALK、ROS1基因突变检测试剂盒”等。鹍远基因也于2018年推出了检测结直肠癌甲基化水平的产品“常乐思”。
发明内容
综上所述，针对目前多癌检测产品的缺乏和技术限制，本文提供了一种探针组合物，可用于肺癌、肝癌和胰腺癌等3种实质性器官肿瘤的早期筛查。该探针组合物可以：1)以非侵入性的方式用于无症状人群的早期筛查，以及癌症患者的预后检测，降低了侵入性检测造成的危害，2)加大了测序深度，使检测基因的广度优于现有的技术和产品，具有通量高，检测速度较快，均摊到每个基因的检测成本低等特点，3)能够实现对肿瘤各部分和所有转移灶的采样，克服肿瘤异质性，和4)具有更高的灵敏度和准确性，能够实现实时监测，甚至有可能通过基因组信息预测发生病变的部位有效延长患者生存期。
具体地，本文涉及如下内容：
1.一种探针组合物，其包括：靶向肺癌、肝癌和胰腺癌中的任意癌症的特异性区域的探针，其中，所述癌症特异性区域选自Seq ID No.：1-62中的 任意。
2.根据第1项所述的探针组合物，其还包括：靶向泛癌特异性区域的探针，所述泛癌特异性区域选自Seq ID No.：63-64中的任意。
3.根据第1项所述的探针组合物，其还包括：靶向组织特异性区域的探针，所述组织特异性区域选自Seq ID No.：65-81中的任意。
4.根据第3项所述的探针组合物，其特征在于，在所述组织特异性区域中，Seq ID No.：65-68、71-75是肺的组织特异性靶区域。
5.根据第3项所述的探针组合物，其特征在于，在所述组织特异性区域中，Seq ID No.：69-70、76是肝的组织特异性靶区域。
6.根据第3项所述的探针组合物，其特征在于，在所述组织特异性区域中，Seq ID No.：77-81是胰腺癌的组织特异性靶区域。
7.根据第1-6项中任一项所述的探针组合物，其包括：
低甲基化探针，其与经重亚硫酸盐转化的不含CG甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交，和
高甲基化探针，其与经重亚硫酸盐转化的CG全部甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交。
8.根据第7项所述的探针组合物，其中所述探针组合物中的每一个探针的长度为40～60bp。
9.根据第8项所述的探针组合物，其中所述探针组合物中的每一个探针的长度为45～56bp，优选50～56bp，进一步优选50bp。
10.根据第7项所述的探针组合物，其特征在于，所述低甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：82-178中的任意，靶向泛癌特异性区域的探针Seq ID No.：179-180中的任意，和靶向组织特异性区域的探针Seq ID No.：181-199中的任意。
11.根据第7项所述的探针组合物，其特征在于，所述高甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：200-296中的任意，靶向泛癌特异性区域的探针Seq ID No.：297-298中的任意，和靶向组织特异性区域的探针Seq ID No.：299-317中的任意。
12.一种试剂盒，其包括第1-11项中任一项所述的探针组合物。
13.一种第1-11项中任一项所述的探针组合物在制备检测肺癌、肝癌和 胰腺癌的试剂盒中的应用。
14.一种芯片，其上固定有包括权利要求1-11中任一项所述的探针组合物。
本文还提供了一种利用所述探针组合物检测肺癌、肝癌和胰腺癌等3种实质性器官肿瘤的方法。
本文同时也提供了一种利用所述试剂盒同时检测上述3种癌症的甲基化水平改变的方法。
由于现有癌症检测技术的局限性，因此，需要开发一种具有以下优势的探针组合物：
1液体活检属于无创肿瘤检测，对于无法获取组织样品的无症状人群和病人群体均能适用。
2可以同时检测3种中国常见实质性器官肿瘤的甲基化水平改变，覆盖超过80％的癌症发病人群。
3为增加检测的准确性，对于每一种癌症，平均测序深度超过5000X。
4对于受检人，一次性可以完成所有高发癌症的筛查，提高了检测效率，每个标志物的平均价格低于市场现有单标志物的检测。
5对于企业，用一个Panel可以完成对主要癌症的筛选，节约了探针合成成本，可以简化实验流程，便于实验员操作。
6原则上也可以用于癌症患者预后的癌症监测。
附图说明
图1为本文的实施操作流程
具体实施方式
本文提供了一种癌症基因甲基化检测的探针组合物。基于高通量测序(NGS)方法检测肺癌、肝癌和胰腺癌等3种实质性器官肿瘤游离DNA甲基化水平变化。其可以以非侵入的方式同时检测3种常见癌症的甲基化水平改变，灵敏性和准确定高，测序深度深且成本低，适用于无法获取组织样品的无症状人群和病人群体，以及癌症患者预后的癌症监测。
定义
除非在本文的其他地方具体限定，否则本文使用的所有其他技术和科学术语具有本文所属领域的普通技术人员通常理解的含义。
探针为长度在几十到几百甚至上千碱基对的单链或双链DNA，其可利用分子的变性、复性以及碱基互补配对的高度精确性，能与待测样本中互补的非标记单链DNA或RNA以氢键结合(杂交)，形成双链复合物(杂交体)。将未配对结合的探针洗去后，可用放射自显影或酶联反应等检测系统检测杂交反应结果。在本文中，与探针互补结合或杂交的区域为特异性靶区域。多个探针组合成探针组合物。
癌症特异性区域是指在少部分癌症种类中，与正常的对照组织相比，该区域的甲基化水平存在显著差异。
泛癌特异性区域是指在大部分癌症种类中，与正常的对照组织相比，该区域的甲基化水平存在显著差异。
组织特异性区域是指该区域在特定组织中的甲基化水平与其他组织相比存在显著差异。
DNA甲基化是指发生在CpG二核苷酸中胞嘧啶上第5位碳原子的甲基化过程，作为一种对稳定的修饰状态，在DNA甲基转移酶的作用下，可随DNA的复制过程遗传给新生的子代DNA，是一种重要的表观遗传机制，DNA甲基化时，基因启动子区的甲基化可导致抑癌基因转录沉寂，因此它与肿瘤的发生关系密切。异常甲基化包括抑癌基因和DNA修复基因的高甲基化、重复序列DNA的低甲基化、某些基因的印记丢失，其与多种肿瘤的发生有关。
在本文中，Panel是指本文中使用的探针组合物。
以下详细描述本文的技术方案。
在本文的一个具体的实施方案中，一种探针组合物，包括：靶向肺癌、肝癌和胰腺癌中的任意癌症的特异性区域的探针，其中，所述癌症特异性区域选自Seq ID No.：1-62中的任意；靶向泛癌特异性区域的探针，所述泛癌特异性区域选自Seq ID No.：63-64中的任意；和靶向组织特异性区域的探针，所述组织特异性区域选自Seq ID No.：65-81中的任意。在所述组织特异性区域中，Seq ID No.：65-68、71-75是肺的组织特异性靶区域。
在本文的一个具体的实施方案中，一种探针组合物，包括：靶向肺癌、肝癌和胰腺癌中的任意癌症的特异性区域的探针，其中，所述癌症特异性区域选自Seq ID No.：1-62中的任意；靶向泛癌特异性区域的探针，所述泛癌特异性区域选自Seq ID No.：63-64中的任意；和靶向组织特异性区域的探针，所述组织特异性区域选自Seq ID No.：65-81中的任意。在所述组织特异性区域中，Seq ID No.：69-70、76是肝的组织特异性靶区域。
在本文的一个具体的实施方案中，一种探针组合物，包括：靶向肺癌、肝癌和胰腺癌中的任意癌症的特异性区域的探针，其中，所述癌症特异性区域选自Seq ID No.：1-62中的任意；靶向泛癌特异性区域的探针，所述泛癌特异性区域选自Seq ID No.：63-64中的任意；和靶向组织特异性区域的探针，所述组织特异性区域选自Seq ID No.：65-81中的任意。在所述组织特异性区域中，Seq ID No.：77-81是胰腺癌的组织特异性靶区域。
在本文的一个具体的实施方案中，上述探针组合物，包括低甲基化探针，其与经重亚硫酸盐转化的不含CG甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交，和高甲基化探针，其与经重亚硫酸盐转化的CG全部甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交。所述低甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：82-178中的任意，靶向泛癌特异性区域的探针Seq ID No.：179-180中的任意，和靶向组织特异性区域的探针Seq ID No.：181-199中的任意。所述高甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：200-296中的任意，靶向泛癌特异性区域的探针Seq ID No.：297-298中的任意，和靶向组织特异性区域的探针Seq ID No.：299-317中的任意。
如下表1所示，其中Seq ID No.82、Seq ID No.83和Seq ID No.84均是靶向Seq ID No.1所示靶区域的低甲基化探针，Seq ID No.200、Seq ID No.201和Seq ID No.202均是靶向Seq ID No.1所示靶区域的高甲基化探针。Seq ID No.85和Seq ID No.86均是靶向Seq ID No.2所示靶区域的低甲基化探针，Seq ID No.203和Seq ID No.204均是靶向Seq ID No.2所示靶区域的高甲基化探针。Seq ID No.87和Seq ID No.88均是靶向Seq ID No.3所示靶区域的低甲基化探针，Seq ID No.205和Seq ID No.206均是靶向Seq ID No.3所示靶区域的高甲基化探针。Seq ID No.89是靶向Seq ID No.4所示靶区域的低 甲基化探针，Seq ID No.207是靶向Seq ID No.4所示靶区域的高甲基化探针。Seq ID No.90和Seq ID No.91均是靶向Seq ID No.5所示靶区域的低甲基化探针，Seq ID No.208和Seq ID No.209均是靶向Seq ID No.3所示靶区域的高甲基化探针。Seq ID No.92是靶向Seq ID No.6所示靶区域的低甲基化探针，Seq ID No.210是靶向Seq ID No.6所示靶区域的高甲基化探针。Seq ID No.93是靶向Seq ID No.7所示靶区域的低甲基化探针，Seq ID No.211是靶向Seq ID No.7所示靶区域的高甲基化探针。Seq ID No.94和Seq ID No.95均是靶向Seq ID No.8所示靶区域的低甲基化探针，Seq ID No.212和Seq ID No.213均是靶向Seq ID No.8所示靶区域的高甲基化探针。Seq ID No.96、Seq ID No.97和Seq ID No.98均是靶向Seq ID No.9所示靶区域的低甲基化探针，Seq ID No.214、Seq ID No.215和Seq ID No.216均是靶向Seq ID No.9所示靶区域的高甲基化探针。Seq ID No.99是靶向Seq ID No.10所示靶区域的低甲基化探针，Seq ID No.217是靶向Seq ID No.10所示靶区域的高甲基化探针。Seq ID No.100是靶向Seq ID No.11所示靶区域的低甲基化探针，Seq ID No.218是靶向Seq ID No.11所示靶区域的高甲基化探针。Seq ID No.101是靶向Seq ID No.12所示靶区域的低甲基化探针，Seq ID No.219是靶向Seq ID No.12所示靶区域的高甲基化探针。Seq ID No.102是靶向Seq ID No.13所示靶区域的低甲基化探针，Seq ID No.220是靶向Seq ID No.13所示靶区域的高甲基化探针。Seq ID No.103和Seq ID No.104均是靶向Seq ID No.14所示靶区域的低甲基化探针，Seq ID No.221和Seq ID No.222均是靶向Seq ID No.14所示靶区域的高甲基化探针。Seq ID No.105和Seq ID No.106均是靶向Seq ID No.15所示靶区域的低甲基化探针，Seq ID No.223和Seq ID No.224均是靶向Seq ID No.15所示靶区域的高甲基化探针。Seq ID No.107和Seq ID No.108均是靶向Seq ID No.16所示靶区域的低甲基化探针，Seq ID No.225和Seq ID No.226均是靶向Seq ID No.16所示靶区域的高甲基化探针。Seq ID No.109和Seq ID No.110均是靶向Seq ID No.17所示靶区域的低甲基化探针，Seq ID No.227和Seq ID No.228均是靶向Seq ID No.17所示靶区域的高甲基化探针。Seq ID No.111是靶向Seq ID No.18所示靶区域的低甲基化探针，Seq ID No.229是靶向Seq ID No.18所示靶区域的高甲基化探针。Seq ID No.112和Seq ID No.113均是靶向Seq ID No.19所示靶区域的低甲基化探 针，Seq ID No.230和Seq ID No.231均是靶向Seq ID No.19所示靶区域的高甲基化探针。Seq ID No.114是靶向Seq ID No.20所示靶区域的低甲基化探针，Seq ID No.232是靶向Seq ID No.20所示靶区域的高甲基化探针。Seq ID No.115是靶向Seq ID No.21所示靶区域的低甲基化探针，Seq ID No.233是靶向Seq ID No.21所示靶区域的高甲基化探针。Seq ID No.116是靶向Seq ID No.22所示靶区域的低甲基化探针，Seq ID No.234是靶向Seq ID No.22所示靶区域的高甲基化探针。Seq ID No.117、Seq ID No.118和Seq ID No.119均是靶向Seq ID No.23所示靶区域的低甲基化探针，Seq ID No.235、Seq ID No.236和Seq ID No.237均是靶向Seq ID No.23所示靶区域的高甲基化探针。Seq ID No.120和Seq ID No.121均是靶向Seq ID No.24所示靶区域的低甲基化探针，Seq ID No.238和Seq ID No.239均是靶向Seq ID No.24所示靶区域的高甲基化探针。Seq ID No.122和Seq ID No.123均是靶向Seq ID No.25所示靶区域的低甲基化探针，Seq ID No.240和Seq ID No.241均是靶向Seq ID No.25所示靶区域的高甲基化探针。Seq ID No.124和Seq ID No.125均是靶向Seq ID No.26所示靶区域的低甲基化探针，Seq ID No.242和Seq ID No.243均是靶向Seq ID No.26所示靶区域的高甲基化探针。Seq ID No.126是靶向Seq ID No.27所示靶区域的低甲基化探针，Seq ID No.244是靶向Seq ID No.27所示靶区域的高甲基化探针。Seq ID No.127和Seq ID No.128均是靶向Seq ID No.28所示靶区域的低甲基化探针，Seq ID No.245和Seq ID No.246均是靶向Seq ID No.28所示靶区域的高甲基化探针。Seq ID No.129和Seq ID No.130均是靶向Seq ID No.29所示靶区域的低甲基化探针，Seq ID No.247和Seq ID No.248均是靶向Seq ID No.29所示靶区域的高甲基化探针。Seq ID No.131是靶向Seq ID No.30所示靶区域的低甲基化探针，Seq ID No.249是靶向Seq ID No.30所示靶区域的高甲基化探针。Seq ID No.132和Seq ID No.133均是靶向Seq ID No.31所示靶区域的低甲基化探针，Seq ID No.250和Seq ID No.251均是靶向Seq ID No.31所示靶区域的高甲基化探针。Seq ID No.134是靶向Seq ID No.32所示靶区域的低甲基化探针，Seq ID No.252是靶向Seq ID No.32所示靶区域的高甲基化探针。Seq ID No.135和Seq ID No.136均是靶向Seq ID No.33所示靶区域的低甲基化探针，Seq ID No.253和Seq ID No.254均是靶向Seq ID No.33所示靶区域的高甲基化探针。Seq ID  No.137是靶向Seq ID No.34所示靶区域的低甲基化探针，Seq ID No.255是靶向Seq ID No.34所示靶区域的高甲基化探针。Seq ID No.138和Seq ID No.139均是靶向Seq ID No.35所示靶区域的低甲基化探针，Seq ID No.256和Seq ID No.257均是靶向Seq ID No.35所示靶区域的高甲基化探针。Seq ID No.140是靶向Seq ID No.36所示靶区域的低甲基化探针，Seq ID No.258是靶向Seq ID No.36所示靶区域的高甲基化探针。Seq ID No.141和Seq ID No.142均是靶向Seq ID No.37所示靶区域的低甲基化探针，Seq ID No.259和Seq ID No.260均是靶向Seq ID No.37所示靶区域的高甲基化探针。Seq ID No.143和Seq ID No.144均是靶向Seq ID No.38所示靶区域的低甲基化探针，Seq ID No.261和Seq ID No.262均是靶向Seq ID No.38所示靶区域的高甲基化探针。Seq ID No.145是靶向Seq ID No.39所示靶区域的低甲基化探针，Seq ID No.263是靶向Seq ID No.39所示靶区域的高甲基化探针。Seq ID No.146和Seq ID No.147均是靶向Seq ID No.40所示靶区域的低甲基化探针，Seq ID No.264和Seq ID No.265均是靶向Seq ID No.40所示靶区域的高甲基化探针。Seq ID No.148是靶向Seq ID No.41所示靶区域的低甲基化探针，Seq ID No.266是靶向Seq ID No.41所示靶区域的高甲基化探针。Seq ID No.149是靶向Seq ID No.42所示靶区域的低甲基化探针，Seq ID No.267是靶向Seq ID No.42所示靶区域的高甲基化探针。Seq ID No.150是靶向Seq ID No.43所示靶区域的低甲基化探针，Seq ID No.268是靶向Seq ID No.43所示靶区域的高甲基化探针。Seq ID No.151是靶向Seq ID No.44所示靶区域的低甲基化探针，Seq ID No.269是靶向Seq ID No.44所示靶区域的高甲基化探针。Seq ID No.152和Seq ID No.153均是靶向Seq ID No.45所示靶区域的低甲基化探针，Seq ID No.270和Seq ID No.271均是靶向Seq ID No.45所示靶区域的高甲基化探针。Seq ID No.154是靶向Seq ID No.46所示靶区域的低甲基化探针，Seq ID No.272是靶向Seq ID No.46所示靶区域的高甲基化探针。Seq ID No.155是靶向Seq ID No.47所示靶区域的低甲基化探针，Seq ID No.273是靶向Seq ID No.47所示靶区域的高甲基化探针。Seq ID No.156是靶向Seq ID No.48所示靶区域的低甲基化探针，Seq ID No.274是靶向Seq ID No.48所示靶区域的高甲基化探针。Seq ID No.157是靶向Seq ID No.49所示靶区域的低甲基化探针，Seq ID No.275是靶向Seq ID No.49所示靶区 域的高甲基化探针。Seq ID No.158是靶向Seq ID No.50所示靶区域的低甲基化探针，Seq ID No.276是靶向Seq ID No.50所示靶区域的高甲基化探针。Seq ID No.159和Seq ID No.160均是靶向Seq ID No.51所示靶区域的低甲基化探针，Seq ID No.277和Seq ID No.278均是靶向Seq ID No.51所示靶区域的高甲基化探针。Seq ID No.161是靶向Seq ID No.52所示靶区域的低甲基化探针，Seq ID No.279是靶向Seq ID No.52所示靶区域的高甲基化探针。Seq ID No.162和Seq ID No.163均是靶向Seq ID No.53所示靶区域的低甲基化探针，Seq ID No.280和Seq ID No.281均是靶向Seq ID No.53所示靶区域的高甲基化探针。Seq ID No.164是靶向Seq ID No.54所示靶区域的低甲基化探针，Seq ID No.282是靶向Seq ID No.54所示靶区域的高甲基化探针。Seq ID No.165和Seq ID No.166均是靶向Seq ID No.55所示靶区域的低甲基化探针，Seq ID No.283和Seq ID No.284均是靶向Seq ID No.55所示靶区域的高甲基化探针。Seq ID No.167和Seq ID No.168均是靶向Seq ID No.56所示靶区域的低甲基化探针，Seq ID No.285和Seq ID No.286均是靶向Seq ID No.56所示靶区域的高甲基化探针。Seq ID No.169和Seq ID No.170均是靶向Seq ID No.57所示靶区域的低甲基化探针，Seq ID No.287和Seq ID No.288均是靶向Seq ID No.57所示靶区域的高甲基化探针。Seq ID No.171和Seq ID No.172均是靶向Seq ID No.58所示靶区域的低甲基化探针，Seq ID No.289和Seq ID No.290均是靶向Seq ID No.58所示靶区域的高甲基化探针。Seq ID No.173和Seq ID No.174均是靶向Seq ID No.59所示靶区域的低甲基化探针，Seq ID No.291和Seq ID No.292均是靶向Seq ID No.59所示靶区域的高甲基化探针。Seq ID No.175是靶向Seq ID No.60所示靶区域的低甲基化探针，Seq ID No.293是靶向Seq ID No.60所示靶区域的高甲基化探针。Seq ID No.176和Seq ID No.177均是靶向Seq ID No.61所示靶区域的低甲基化探针，Seq ID No.294和Seq ID No.295均是靶向Seq ID No.61所示靶区域的高甲基化探针。Seq ID No.178是靶向Seq ID No.62所示靶区域的低甲基化探针，Seq ID No.296是靶向Seq ID No.62所示靶区域的高甲基化探针。Seq ID No.179是靶向Seq ID No.63所示靶区域的低甲基化探针，Seq ID No.297是靶向Seq ID No.63所示靶区域的高甲基化探针。Seq ID No.180是靶向Seq ID No.64所示靶区域的低甲基化探针，Seq ID No.298是靶向Seq ID No.64所示 靶区域的高甲基化探针。Seq ID No.181是靶向Seq ID No.65所示靶区域的低甲基化探针，Seq ID No.299是靶向Seq ID No.65所示靶区域的高甲基化探针。Seq ID No.182是靶向Seq ID No.66所示靶区域的低甲基化探针，Seq ID No.300是靶向Seq ID No.66所示靶区域的高甲基化探针。Seq ID No.183是靶向Seq ID No.67所示靶区域的低甲基化探针，Seq ID No.301是靶向Seq ID No.67所示靶区域的高甲基化探针。Seq ID No.184是靶向Seq ID No.68所示靶区域的低甲基化探针，Seq ID No.302是靶向Seq ID No.68所示靶区域的高甲基化探针。Seq ID No.185是靶向Seq ID No.69所示靶区域的低甲基化探针，Seq ID No.303是靶向Seq ID No.69所示靶区域的高甲基化探针。Seq ID No.186是靶向Seq ID No.70所示靶区域的低甲基化探针，Seq ID No.304是靶向Seq ID No.70所示靶区域的高甲基化探针。Seq ID No.187和Seq ID No.188均是靶向Seq ID No.71所示靶区域的低甲基化探针，Seq ID No.305和Seq ID No.306均是靶向Seq ID No.71所示靶区域的高甲基化探针。Seq ID No.189是靶向Seq ID No.72所示靶区域的低甲基化探针，Seq ID No.307是靶向Seq ID No.72所示靶区域的高甲基化探针。Seq ID No.190是靶向Seq ID No.73所示靶区域的低甲基化探针，Seq ID No.308是靶向Seq ID No.73所示靶区域的高甲基化探针。Seq ID No.191是靶向Seq ID No.74所示靶区域的低甲基化探针，Seq ID No.309是靶向Seq ID No.74所示靶区域的高甲基化探针。Seq ID No.192是靶向Seq ID No.75所示靶区域的低甲基化探针，Seq ID No.310是靶向Seq ID No.75所示靶区域的高甲基化探针。Seq ID No.193是靶向Seq ID No.76所示靶区域的低甲基化探针，Seq ID No.311是靶向Seq ID No.76所示靶区域的高甲基化探针。Seq ID No.194是靶向Seq ID No.77所示靶区域的低甲基化探针，Seq ID No.312是靶向Seq ID No.77所示靶区域的高甲基化探针。Seq ID No.195是靶向Seq ID No.78所示靶区域的低甲基化探针，Seq ID No.313是靶向Seq ID No.78所示靶区域的高甲基化探针。Seq ID No.196是靶向Seq ID No.79所示靶区域的低甲基化探针，Seq ID No.314是靶向Seq ID No.79所示靶区域的高甲基化探针。Seq ID No.197和Seq ID No.198均是靶向Seq ID No.80所示靶区域的低甲基化探针，Seq ID No.315和Seq ID No.316均是靶向Seq ID No.80所示靶区域的高甲基化探针。Seq ID No.199是靶向Seq ID No.81所示靶区域的低甲基化探针， Seq ID No.317是靶向Seq ID No.81所示靶区域的高甲基化探针。表1中给出了探针所靶向的靶序列。
在本文的一个具体的实施方案中，上述探针组合物中的每一个探针的长度为40～60bp，优选为45～56bp，优选为50～56bp，进一步优选为50bp。
本文还提供了一种试剂盒。
在本文的一个具体的实施方案中，所述试剂盒包括上述任一实施方案所述的探针组合物。
本文还提供了探针组合物的用途。
在本文的一个具体的实施方案中，上述探针组合物用于制备检测肺癌、肝癌和胰腺癌的试剂盒。
本文还提供了一种芯片。
在本文的一个具体的实施方案中，所述芯片上固定有上述任一实施方案所述的探针组合物。
本文还提供了一种利用所述探针组合物检测肺癌、肝癌和胰腺癌等3种实质性器官肿瘤的方法。
在本文的一个具体的实施方案中，所述检测方法采用杂交捕获的方式富集cfDNA，并用NGS技术检测与癌症高度相关的甲基化位点。覆盖了我国发病率最高的3种实质性器官恶性肿瘤(肺癌、肝癌和胰腺癌)。最终，根据检测血浆cfDNA中基因甲基化变化水平，为多癌早筛和早诊提供信息。
本申请同时也提供了一种利用所述试剂盒同时检测上述3种癌症的甲基化水平改变的方法。
具体来说，本申请涉及受试者3种癌症体外检测方法，包括以下步骤：采集受试者样品；提取纯化所述样品中的DNA；针对纯化的DNA样品构建用于测序的DNA文库；用重亚硫酸盐转化所述构建的DNA文库；预PCR扩增所述经重亚硫酸盐转化的DNA文库；利用探针组合物对经预PCR扩增的样品进行杂交捕获；利用PCR扩增经杂交捕获后的产物；对PCR扩增后的经杂交捕获后的产物进行高通量二代测序；对测序数据进行分析，确定样本的甲基化水平；基于所述样本的甲基化水平判读所述患者的患病情况。
具体来说，所述受试者疑似患有癌症。具体来说，采集受试者的样品为血浆样品。具体来说，所述转化为使用重亚硫酸盐处理。
具体来说，所述探针组合物包括：靶向泛癌特异性区域的2个探针，靶向癌症特异性区域的n个探针，和靶向组织特异性区域的m个探针。所述探针组合物包括：低甲基化探针，其与经重亚硫酸盐转化的不含CG甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交，和高甲基化探针，其与经重亚硫酸盐转化的CG全部甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交。所述探针组合物中的每一个探针的长度为40～60bp。例如，所述探针组合物中的每一个探针的长度为45～56bp，优选50～56bp，进一步优选50bp。
具体来说，所述探针组合物中的n个探针靶向癌症特异性区域，其中，n为选自1-192中的任意的整数；其中，所述癌症特异性区域选自Seq ID No.：1-62中的任意。所述探针组合物中的m个探针靶向所述组织特异性区域，其中，m为选自1-116中的任意的整数；其中，所述组织特异性区域选自Seq ID No.：65-81中的任意。所述低甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：82-178中的任意，靶向泛癌特异性区域的探针Seq ID No.：179-180中的任意，和靶向组织特异性区域的探针Seq ID No.：181-199中的任意。所述高甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：200-296中的任意，靶向泛癌特异性区域的探针Seq ID No.：297-298中的任意，和靶向组织特异性区域的探针Seq ID No.：299-317中的任意。
具体来说，所述判读包括以下步骤：(1)比对泛癌特异性区域数据库，并进行判读以确认受试者是否患有癌症；(2)比对癌症特异性区域数据库，并进行判读以确认受试者患有的癌症为几种疑似癌症中的一种；(3)比对组织特异性区域数据库，并进行判读以确认受试者患癌的部位。所述步骤(1)包括进行如下判读：判断所述泛癌特异性区域Seq ID No.：63的甲基化水平是否大于等于55％，并且所述泛癌特异性区域Seq ID No.：64的甲基化水平是否大于等于60％，则判读所述患者患有癌症。所述步骤(2)包括进行如下判读：如果在靶向所述癌症特异性区域的n个探针中，n1个探针靶向的区域的甲基化水平大于等于各自阈值，且n1/n≥20％，优选n1/n≥30％，则判读患者患有组织特异性癌症中的任意一种。所述步骤(3)包括进行如下判读：在靶向所述组织特异性区域的m个探针中m1个探针靶向的区域的甲基化水平大于等于各自阈值，则进一步分析大于等于各自阈值的m1个探针所靶向的组织 并计数每一个组织大于等于阈值的探针的个数，判读认为患者罹患癌症的组织是甲基化水平大于等于阈值的探针个数最多的组织。下表1中也给出了各靶区域的甲基化的阈值。
表1本申请中涉及的序列
Figure PCTCN2021079075-appb-000001
Figure PCTCN2021079075-appb-000002
Figure PCTCN2021079075-appb-000003
Figure PCTCN2021079075-appb-000004
Figure PCTCN2021079075-appb-000005
Figure PCTCN2021079075-appb-000006
Figure PCTCN2021079075-appb-000007
Figure PCTCN2021079075-appb-000008
Figure PCTCN2021079075-appb-000009
Figure PCTCN2021079075-appb-000010
Figure PCTCN2021079075-appb-000011
实施例
实施例1：
如图1所示，本申请的实施流程具体如下：
1.1.cfDNA提取纯化
1.1.1.血浆样本制备：
4℃、2000g离心血液样本10min,将血浆转移到一个新的离心管中。4℃、16000g离心血浆样本10min,根据使用的收集管类型，执行下一步,本实验中使用的收集管类型为其他。
表2
Figure PCTCN2021079075-appb-000012
1.1.2.裂解和结合
1.1.2.1.按照下表准备结合溶液/珠子混合物，然后彻底混匀。
表3
Figure PCTCN2021079075-appb-000013
加入适量体积的血浆样品。
1.1.2.2.彻底混匀血浆样品和结合溶液/珠子混合物。
1.1.2.3.在旋转混匀仪上充分的结合10min，使cfDNA结合到磁珠上。
1.1.2.4.将结合管放在磁力架上5min，直到溶液变得澄清，磁珠完全吸附在磁力架上。
1.1.2.5.用移液管小心的弃去上清，继续保持管子在磁力架上几分钟，用移液管移去残留上清。
1.1.3.洗涤
1.1.3.1.将珠子重悬在1ml洗涤溶液中。
1.1.3.2.将重悬液转移到新的无吸附1.5ml离心管中。保留结合管。
1.1.3.3.将含有珠子重悬液的离心管置于磁力架上，20s。
1.1.3.4.将分离得到的上清，吸出洗涤结合管，将清洗后的残留珠子再次收集到重悬液中，弃掉裂解/结合管。
1.1.3.5.管子置于磁力架上2min，直到溶液变得澄清，珠子聚集在磁力架，用1ml移液器移除上清。
1.1.3.6.管子留在磁力架上，用200μL移液器尽可能移除残留的液体。
1.1.3.7.将管子从磁力架取下来，加入1ml洗涤溶液，涡旋30s。
1.1.3.8.置于磁力架2min，直到溶液澄清，珠子聚集在磁力架上，用1ml移液管移除上清。
1.1.3.9.管子留在磁力架上，用200μL移液器彻底移除残留液体。
1.1.3.10.将管子从磁力架取下，加入1ml 80％乙醇，涡旋30s。
1.1.3.11.置于磁力架上2min，溶液变得澄清，用1ml移液器移去上清。
1.1.3.12.管子留在磁力架上，用200μL移液器移去残留液体。
1.1.3.13.用80％乙醇重复上述1.1.3.10.-1.1.3.12.步骤一次，尽可能除去上清。
1.1.3.14.管子留在磁力架上，空气中干燥珠子3～5分钟。
1.1.4.洗脱cfDNA
1.1.4.1.按照下表加入洗脱液。
表4
Figure PCTCN2021079075-appb-000014
1.1.4.2.涡旋5min，置于磁力架上2min，溶液变得澄清，吸取上清液中的cfDNA。
1.1.4.3.纯化的cfDNA立即使用，或者将上清转移至新的离心管中，-20℃保存。
1.2.gDNA打断与纯化：
1.2.1.按照Qubit浓度，取2μg gDNA，加水补至125μl，加入到covaris130μl打断管中，设置程序：50W，20％，200个循环，250s。
1.2.2.打断结束后取1μl样品使用Agilent2100进行片段检测，正常打断后样品检测主峰约在150bp-200bp。
对于cfDNA样品，Agilent2100进行片段检测，直接Qubit用于后续的实验。
1.3.末端修复、3‘端加“A”：
1.3.1.取20ng打断后的gDNA或cfDNA至PCR管中，用无核酸酶水补至50μl，加入以下试剂，涡旋混匀：
表5
组分 体积
gDNA/cfDNA 50μl
终止修复和A加尾缓冲液 7μl
终止修复和A加尾酶混合物 3μl
总体积 60μl
1.3.2.设置以下程序在PCR仪上进行反应：热盖温度85℃。
表6
温度 时间
20℃ 30min
65℃ 30min
4℃ ∞
1.4.接头连接及纯化：
1.4.1.参照下表将接头提前稀释成合适的浓度：
表7
每50ul ER和AT反应的片段化的DNA 接头浓度
1μg 10uM
500ng 10uM
250ng 10uM
100ng 10uM
50ng 10uM
25ng 10uM
10ng 3uM
5ng 5uM
2.5ng 2.5uM
1ng 625nM
1.4.2.按下表配制以下试剂，轻轻吸打混匀，短暂离心：
表8
组分 体积
末端修复、加“A”反应产物 60μl
接头 5μl
无核酸酶水 5μl
连接缓冲液 30μl
DNA连接酶 10μl
总体积 110μl
1.4.3.设置以下程序在PCR仪上进行反应：无热盖。
表9
温度 时间
20℃ 30min
4℃ ∞
1.4.4.按照以下体系，加入纯化磁珠进行实验(Agencourt AMPure XP磁珠提前拿至室温震荡混合均匀备用)：
表10
组分 体积
接头连接产物 110μl
Agencourt AMPure XP珠子 110μl
总体积 220μl
1.4.4.1.轻轻吸打混匀6次。
1.4.4.2.室温静置孵育5-15min，将PCR管置于磁力架上3min使溶液澄清。
1.4.4.3.移除上清，PCR管继续放置在磁力架上，向PCR管内加入200μl80％乙醇溶液，静置30s。
1.4.4.4.移除上清，再向PCR管内加入200μl 80％乙醇溶液，静置30s后彻底移除上清(建议使用10μl移液器移除底部残留乙醇溶液)。
1.4.4.5.室温静置3-5min，使残留乙醇彻底挥发。
1.4.4.6.加入22μl的无核酸酶水，把PCR管从磁力架取下，轻轻吸打重悬磁珠，避免产生气泡，室温静置2min。
1.4.4.7.将PCR管置于磁力架上2min使溶液澄清。
1.4.4.8.用移液器吸取20μl上清液，转移到新的PCR管。
1.5重亚硫酸盐处理及纯化：
1.5.1.预先拿出所需要的试剂，并溶解。根据下表加入各试剂：
表11
组分 高浓度样品(1ng-2μg)体积 低浓度样品(1-500ng)体积
接头连接纯化产物 20μl 40μl
重亚硫酸盐溶液 85μl 85μl
DNA保护缓冲液 35μl 15μl
总体积 140μl 140μl
1.5.2.DNA保护缓冲液加入液体变成蓝色。轻轻吸打混匀，然后分成两管至于PCR仪上。
1.5.3.设置以下程序，并运行：热盖105℃。
表12
温度 时间
95℃ 5min
60℃ 10min
95℃ 5min
60℃ 10min
4℃ ∞
1.5.4.简短离心将两管相同样本合并至同一个干净的1.5ml离心管中。
1.5.5.每个样本中加入310μl缓冲液BL(样本量少于100ng加入1μl的载体RNA(1μg/μl))，涡旋混匀，简短离心。
1.5.6.加入250μl无水乙醇到每个样本中，涡旋混匀15s，简短离心，将混合液加入到准备好的对应的离心柱中。
1.5.7.静置1min，离心1min，将收集管中的液体重新转移到离心柱中，离心1min，弃去离心管的液体。
1.5.8.加入500μl缓冲液BW(注意是否加入无水乙醇)，离心1min，弃去废液。
1.5.9.加入500μl缓冲液BD(注意是否加入无水乙醇)，盖好管盖，室温放置15min。离心1min，弃去离心下的液体。
1.5.10.加入500μl缓冲液BW(注意是否加入无水乙醇)，离心1min，弃去离下来的液体，在重复一次，共2次。
1.5.11.加入250μl无水乙醇，离心1min，将离心柱放置到新的2ml收集管中，弃掉全部剩余液体。
1.5.12.将离心柱放置到干净的1.5ml离心管中，加入20μl无核酸酶水到离心柱膜中心，轻轻盖上管盖，室温放置1min，离心1min。
1.5.13.将收集管中的液体重新转移至离心柱中，室温放置1min，离心1min。
1.6.杂交前预扩增及纯化：
1.6.1.按下列表格配制反应体系，吹打混匀，短暂离心：
表13
Figure PCTCN2021079075-appb-000015
1.6.2.设置以下程序并启动PCR程序：热盖105℃
表14
Figure PCTCN2021079075-appb-000016
1.6.3.PCR循环数根据投入DNA的量不同进行调整，参考数据如下所示：
表15
Figure PCTCN2021079075-appb-000017
1.6.4.向反应结束后的PCR管中加入50μl Agencourt AMPure XP磁珠，用移液器吹打混匀，避免产生气泡(Agencourt AMPure XP提前室温混匀并平衡)。
1.6.5.室温孵育5-15min，把PCR管置于磁力架上3min使溶液澄清。
1.6.6.移除上清，PCR管继续放置在磁力架上，向PCR管内加入200μl80％乙醇溶液，静置30s。
1.6.7.移除上清，再向PCR管内加入200μl 80％乙醇溶液，静置30s后彻底移除上清(建议使用10μl移液器移除底部残留乙醇溶液)。
1.6.8.室温静置5min，使残留乙醇彻底挥发。
1.6.9.加入30μl的无核酸酶水，将离心管从磁力架取下，使用移液器，轻轻吸打重悬磁珠。
1.6.10.室温静置2min，将200μl PCR管置于磁力架上2min使溶液澄清。
1.6.11.用移液器将上清液转移到新的200μl PCR管中(置于冰盒上)，在反应管上标记好样本号，准备下一步反应。
1.6.12.取1μl样品使用Qubit进行文库浓度测定，记录文库浓度。
1.6.13.取1μl样品使用安捷伦2100进行文库片段长度测定，文库长度约在270bp-320bp间。
1.7.样品与探针杂交：
1.7.1.按照以下体系将样品文库与各种Hyb阻断物混匀，标记为B：
表16
组分 体积
预扩增产物 750ng对应体积
Hyb人阻断物 5μl
接头阻断物 6μl
增强剂 5μl
1.7.2.将准备好的样品和Hyb阻断物混合物放入真空浓缩离心机，打开PCR管盖，启动离心机，打开真空泵开关，开始浓缩。
1.7.3.将抽干的样品重新溶在约9μl无核酸酶水中,总体积10μl，轻轻吸打混匀，短暂离心后置于冰上待用，标记为B。
1.7.4.将Hyb缓冲液置于室温融化，融解之后会有沉淀出现，混匀后置于65℃水浴锅内预热，完全溶解后(无沉淀及浑浊物)取20μl Hyb缓冲液置于新的200μl PCR管内，盖好管盖,标记为A,继续置于65℃水浴锅内孵育待用。
1.7.5.通过艾吉泰康生物科技(北京)有限公司合成以下低甲基化探针：
a)靶向癌症特异性区域的探针Seq ID No.：82-178中的任意，b)靶向泛癌特异性区域的探针Seq ID No.：179-180中的任意，和c)靶向组织特异性区域的探针Seq ID No.：181-199中的任意，
并且合成以下高甲基化探针：
d)靶向癌症特异性区域的探针Seq ID No.：200-296中的任意，e)靶向泛癌特异性区域的探针Seq ID No.：297-298中的任意，和f)靶向组织特异性区域的探针Seq ID No.：299-317中的任意。
并且以a:b:c:d:e:f＝1:1:1:1:1:1的比例制成探针组合物。
1.7.6.取5μl RNA酶阻断物与2μl探针组合物置于200μl PCR管内，轻轻吸打混匀，短暂离心后置于冰上待用，标记为C。
1.7.7.设置PCR仪参数，热盖100℃，95℃，5min；65℃，保持。
1.7.8.将PCR管B置于PCR仪上，运行以上程序。
1.7.9.PCR仪温度降至65℃时，将PCR管A置于PCR仪上孵育，盖上PCR仪热盖。
1.7.10.5min后，将C置于PCR上孵育，盖上PCR仪热盖。
1.7.11.将PCR管C放置入PCR仪2min后，把移液器调至13μl，从PCR管A中吸取13μl Hyb缓冲液移至PCR管C中，吸取全部PCR管B中样品移至PCR管C中，轻轻吸打10次，充分混匀，避免产生大量气泡，密封管盖，盖上PCR仪热盖,65℃孵育过夜(16-24h)。
1.8.捕获目标区域DNA文库：
1.8.1.捕获磁珠的准备
1.8.1.1.将磁珠(Dynabeads MyOne Streptavidin T1磁珠)从4℃取出，涡旋震荡重悬。
1.8.1.2.取50μl磁珠置于新的PCR管内，置于磁力架上1min使溶液澄清，移除上清。
1.8.1.3.从磁力架上取下PCR管，加入200μL结合缓冲液轻轻吸打数次混匀，重悬磁珠。
1.8.1.4.置磁力架上1min，移除上清。
1.8.1.5.重复步骤3-4两次，共清洗磁珠3次。
1.8.1.6.从磁力架上取下PCR管，加入200μL结合缓冲液轻轻吸打6次重悬磁珠待用。
1.8.2.捕获目标DNA文库
1.8.2.1.保持杂交产物PCR管C在PCR仪上，将准备好的200μL捕获磁珠加入到杂交后的产物PCR管C中，用移液器吸打6次混匀，置于旋转混匀仪上室温结合30min(转速最好不要超过10转/min)。
1.8.2.2.将PCR管置于磁力架上2min使溶液澄清，移除上清液。
1.8.2.3.向PCR管C内加入200μL的洗涤缓冲液1，轻轻吸打6次混匀，置于旋转混匀仪上清洗15min(转速最好不要超过10转/min)，然后短暂离心，将PCR管放于磁力架上2min使溶液澄清，移除上清。
1.8.2.4.加入200μl的65℃预热后的洗涤缓冲液2，轻轻吸打6次混匀，置于混匀仪上65℃孵育10min，转速800转/min进行清洗。
1.8.2.5.短暂离心，将PCR管放于磁力架上2min，移除上清。使用洗涤缓冲液2再重复2次清洗，共计3次。最后一次彻底移除洗涤缓冲液2。
1.8.2.6.PCR管继续置于磁力架上，向PCR管内加入200μl 80％乙醇，静置30s后彻底移除乙醇溶液，室温晾干2min。
1.8.2.7.向PCR管加入30μL无核酸酶水，从磁力架上取下PCR管，轻轻吸打6次重悬磁珠待用。
1.9.捕获后扩增及纯化
1.9.1.根据下表配制反应体系进行捕获文库的富集，轻轻吹打混匀后，短暂离心：
表17
Figure PCTCN2021079075-appb-000018
1.9.2.设置以下程序，将样品置于PCR仪中，运行程序：热盖105℃。
表18
Figure PCTCN2021079075-appb-000019
1.9.3.PCR结束后向样品加入55μl Agencourt AMPure XP磁珠，用移液器轻轻吸打混匀。
1.9.4.室温孵育5min，把PCR管置于磁力架上3min使溶液澄清。
1.9.5.移除上清，PCR管继续置于磁力架上，加入200μl 80％无水乙醇，静置30s。
1.9.6.移除上清，再向PCR管内加入200μl 80％无水乙醇，静置30后彻底移除上清。
1.9.7.室温放置5min，使得残留乙醇彻底挥发。
1.9.8.加入25μl无核酸酶水，将PCR管从磁力架拿下，轻轻吹打混匀重悬磁珠，室温放置2min。
1.9.9.将PCR管置于磁力架上2min使溶液澄清。
1.9.10.用移液器吸23μl上清液转移到1.5ml离心管，标记样品信息。
1.9.11.取1μl文库使用Qubit进行定量，记录文库浓度。
1.9.12.取1μl样品使用Agilent2100进行文库片段长度测定。
1.9.13.使用Illumina高通量测序平台进行测序。
1.10.甲基化生信分析流程。大致如下：使用trimmomatic等质控软件查看测序质量，去除低质量的读段，然后采用Bismarker等比对软件将质控后的干净的数据比对到参考基因组上，采用methykit等R包提取相应的甲基化位点。最后，计算出Panel上的每个靶区域的甲基化比率。
实施例2
一例肺癌样本，采用本申请的Panel检测，按实施例1的方法采集外周血；建库，并通过Illumina平台测序；测序数据经上述生物信息的分析流程， 得到甲基化水平，结果如下表19所示(表19显示了检测到的大于等于甲基化阈值的靶区域)。
表19
基因 CHR 起始 终止 甲基化比率 靶区域序列号
TBX15 1 119527108 119527157 0.55 Seq ID No.63
CRYGD 2 208989200 208989249 0.60 Seq ID No.64
FMO3 1 171059887 171059936 0.33 Seq ID No.67
FMO3 1 171060010 171060059 0.33 Seq ID No.68
ITIH3 3 52828746 52828819 0.25 Seq ID No.71
CHST12 7 2473529 2473578 0.51 Seq ID No.72
CHST12 7 2473811 2473860 0.51 Seq ID No.73
RUNX3 1 25257457 25257588 0.60 Seq ID No.1
RUNX3 1 25258133 25258195 0.57 Seq ID No.2
RUNX3 1 25258225 25258285 0.52 Seq ID No.3
APC 5 112073300 112073439 0.39 Seq ID No.23
HOXA11AS 7 27225428 27225497 0.4 Seq ID No.33
HOXA11AS 7 27225523 27225577 0.47 Seq ID No.34
PHOX2A 11 71954934 71954983 0.53 Seq ID No.49
GALR1 18 74961918 74962001 0.49 Seq ID No.61
对检测样本进行模式识别分类鉴定，首先判读出泛癌特异性标志物TBX15和CRYGD基因的甲基化水平大于等于55％和60％，则初步判断该样本为患有癌症的样本；其次，判读出癌症特异性标志物RUNX3、APC、HOXA11AS、PHOX2A、GALR1的甲基化水平均大于等于表1中所示的各自阈值(如上表19所示)，则进一步判断该样本为患有以下11种癌症(食管癌、胃癌、结直肠癌、肺癌、肝癌、胰腺癌、前列腺癌、乳腺癌、卵巢癌、宫颈癌和子宫内膜癌)中的任意癌症的样本；最后，判读组织特异性标志物，基于表19中大于等于各自阈值的靶区域，可以看出属于肺组织特异性的5个靶区域Seq ID No.67、Seq ID No.68、Seq ID No.71、Seq ID No.72和Seq ID No.73大于等于各自的甲基化水平的阈值，没有其他的组织特异性标志物的甲基化大于等于其各自的阈值，因此在大于等于各自甲基化阈值的组织特异性标志物中，肺组织特异性标志物最多，则最终判断该样本为患有肺癌的样本。
患者术后48小时，再次抽血，采用本申请的Panel检测，按实施例1的方法采集外周血，建库，测序；测序数据经上述生物信息的分析流程，通过模式识别的方法，分析所有测序数据，结果显示上表中的基因甲基化水平 回归正常水平。
实施例3
一例肝癌样本，采用本申请的Panel检测，按实施例1的方法采集外周血；建库，并通过Illumina平台测序；测序数据经上述生物信息的分析流程，得到甲基化水平，结果如下表20所示(表20显示了检测到的大于等于甲基化阈值的靶区域)。
表20
基因 CHR 起始 终止 甲基化比率 靶区域序列号
TBX15 1 119527108 119527157 0.55 Seq ID No.63
CRYGD 2 208989200 208989249 0.60 Seq ID No.64
MTHFD2 2 74425523 74425572 0.6 Seq ID No.69
GLI2 2 121570226 121570275 0.43 Seq ID No.70
RASSF1 3 50378359 50378432 0.54 Seq ID No.15
APC 5 112073300 112073439 0.37 Seq ID No.23
TRIM15 6 30131701 30131768 0.48 Seq ID No.31
HOXA11AS 7 27225428 27225497 0.4 Seq ID No.33
HOXA11AS 7 27225523 27225577 0.49 Seq ID No.34
CCND2 12 4381740 4381801 0.43 Seq ID No.51
CCND2 12 4381834 4381883 0.40 Seq ID No.52
对检测样本进行模式识别分类鉴定，首先判读出泛癌特异性标志物TBX15和CRYGD基因的甲基化水平大于等于55％和60％，则初步判断该样本为患有癌症的样本；其次，判读出癌症特异性标志物RASSF1、APC、TRIM15、HOXA11AS、CCND2的甲基化水平均大于等于表1中所示的各自阈值(如上表20所示)，则进一步判断该样本为患有以下11种癌症(食管癌、胃癌、结直肠癌、肺癌、肝癌、胰腺癌、前列腺癌、乳腺癌、卵巢癌、宫颈癌和子宫内膜癌)中的任意癌症的样本；最后，判读组织特异性标志物，基于表20中大于等于各自阈值的靶区域，可以看出属于肝组织特异性的2个靶区域Seq ID No.69和Seq ID No.70大于等于各自的甲基化水平的阈值，没有其他的组织特异性标志物的甲基化大于等于其各自的阈值，因此在大于等于各自甲基化阈值的组织特异性标志物中，肝组织特异性标志物最多，则最终判断该样本为患有肝癌的样本。
患者术后48小时，再次抽血，采用本申请的Panel检测，按实施例1的方法采集外周血，建库，测序；测序数据经上述生物信息的分析流程，通 过模式识别的方法，分析所有测序数据，结果显示上表中的基因甲基化水平回归正常水平。
实施例4
一例胰腺癌样本，采用本申请的Panel检测，按实施例1的方法采集外周血；建库，并通过Illumina平台测序；测序数据经上述生物信息的分析流程，得到甲基化水平，结果如下表21所示(表21显示了检测到的大于等于甲基化阈值的靶区域)。
表21
基因 CHR 起始 终止 甲基化比率 靶区域序列号
TBX15 1 119527108 119527157 0.55 Seq ID No.63
CRYGD 2 208989200 208989249 0.60 Seq ID No.64
FRY 13 32605358 32605407 0.32 Seq ID No.77
FRY 13 32605563 32605612 0.40 Seq ID No.78
FRY 13 32605902 32605951 0.39 Seq ID No.79
BRF1 14 105714785 105714844 0.33 Seq ID No.80
BRF1 14 105715025 105715074 0.38 Seq ID No.81
HOPX 4 57522445 57522494 0.60 Seq ID No.18
SFRP2 4 154710475 154710536 0.38 Seq ID No.19
SFRP2 4 154710598 154710647 0.39 Seq ID No.20
SFRP2 4 154710702 154710751 0.47 Seq ID No.21
SFRP2 4 154710796 154710845 0.53 Seq ID No.22
GFRA1 10 118032831 118032906 0.69 Seq ID No.40
GFRA1 10 118032948 118032997 0.37 Seq ID No.41
HOXB4 17 46655339 46655395 0.42 Seq ID No.59
HOXB4 17 46655428 46655477 0.61 Seq ID No.60
SALL1 16 51184379 51184441 0.63 Seq ID No.58
对检测样本进行模式识别分类鉴定，首先判读出泛癌特异性标志物TBX15和CRYGD基因的甲基化水平大于等于55％和60％，则初步判断该样本为患有癌症的样本；其次，判读出癌症特异性标志物HOPX、SFRP2、GFRA1、HOXB4、SALL1的甲基化水平均大于等于表1中所示的各自阈值(如上表21所示)，则进一步判断该样本为患有以下11种癌症(食管癌、胃癌、结直肠癌、肺癌、肝癌、胰腺癌、前列腺癌、乳腺癌、卵巢癌、宫颈癌和子宫内膜癌)中的任意癌症的样本；最后，判读组织特异性标志物，基于表21中大于等于各自阈值的靶区域，可以看出属于胰腺组织特异性的5个靶区域Seq ID No.77、Seq ID No.78、Seq ID No.79、Seq ID No.80和Seq  ID No.81大于等于各自的甲基化水平的阈值，没有其他的组织特异性标志物的甲基化大于等于其各自的阈值，因此在大于等于各自甲基化阈值的组织特异性标志物中，胰腺组织特异性标志物最多，则最终判断该样本为患有胰腺癌的样本。
患者术后48小时，再次抽血，采用本申请的Panel检测，按实施例1的方法采集外周血，建库，测序；测序数据经上述生物信息的分析流程，通过模式识别的方法，分析所有测序数据，结果显示上表中的基因甲基化水平回归正常水平。
对于本领域的技术人员来说，可以根据以上的技术方案和构思，作出各种相应的改变和变形，而所有的这些改变和变形都应该包括在本申请权利要求的保护范围之内。

Claims (14)

  1. 一种探针组合物，其包括：
    靶向肺癌、肝癌和胰腺癌中的任意癌症的特异性区域的探针，
    其中，所述癌症特异性区域选自Seq ID No.：1-62中的任意。
  2. 根据权利要求1所述的探针组合物，其还包括：
    靶向泛癌特异性区域的探针，
    所述泛癌特异性区域选自Seq ID No.：63-64中的任意。
  3. 根据权利要求1所述的探针组合物，其还包括：
    靶向组织特异性区域的探针，
    所述组织特异性区域选自Seq ID No.：65-81中的任意。
  4. 根据权利要求3所述的探针组合物，其特征在于，在所述组织特异性区域中，Seq ID No.：65-68、71-75是肺的组织特异性靶区域。
  5. 根据权利要求3所述的探针组合物，其特征在于，在所述组织特异性区域中，Seq ID No.：69-70、76是肝的组织特异性靶区域。
  6. 根据权利要求3所述的探针组合物，其特征在于，在所述组织特异性区域中，Seq ID No.：77-81是胰腺癌的组织特异性靶区域。
  7. 根据权利要求1-6中任一项所述的探针组合物，其包括：
    低甲基化探针，其与经重亚硫酸盐转化的不含CG甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交，和
    高甲基化探针，其与经重亚硫酸盐转化的CG全部甲基化的所述癌症特异性区域、泛癌特异性区域、以及组织特异性区域杂交。
  8. 根据权利要求7所述的探针组合物，其中所述探针组合物中的每一个探针的长度为40～60bp。
  9. 根据权利要求8所述的探针组合物，其中所述探针组合物中的每一个探针的长度为45～56bp，优选50～56bp，进一步优选50bp。
  10. 根据权利要求7所述的探针组合物，其特征在于，所述低甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：82-178中的任意，靶向泛癌特异性区域的探针Seq ID No.：179-180中的任意，和靶向组织特异性区域的探针Seq ID No.：181-199中的任意。
  11. 根据权利要求7所述的探针组合物，其特征在于，所述高甲基化探针包括靶向癌症特异性区域的探针Seq ID No.：200-296中的任意，靶向泛癌特异性区域的探针Seq ID No.：297-298中的任意，和靶向组织特异性区域的探针Seq ID No.：299-317中的任意。
  12. 一种试剂盒，其包括权利要求1-11中任一项所述的探针组合物。
  13. 一种权利要求1-11中任一项所述的探针组合物在制备检测肺癌、肝癌和胰腺癌的试剂盒中的应用。
  14. 一种芯片，其上固定有包括权利要求1-11中任一项所述的探针组合物。
PCT/CN2021/079075 2020-03-05 2021-03-04 检测3种实质性器官肿瘤的探针组合物 WO2021175284A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010147485.2 2020-03-05
CN202010147485.2A CN112662761A (zh) 2020-03-05 2020-03-05 一种检测3种实质性器官肿瘤的探针组合物

Publications (1)

Publication Number Publication Date
WO2021175284A1 true WO2021175284A1 (zh) 2021-09-10

Family

ID=75402740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/079075 WO2021175284A1 (zh) 2020-03-05 2021-03-04 检测3种实质性器官肿瘤的探针组合物

Country Status (2)

Country Link
CN (1) CN112662761A (zh)
WO (1) WO2021175284A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116676389A (zh) * 2021-12-31 2023-09-01 博尔诚（北京）科技有限公司 用于肺癌筛查的标志物、探针组合物及其应用
CN117887854A (zh) * 2022-01-24 2024-04-16 博尔诚（北京）科技有限公司 用于胰腺癌筛查的标志物、探针组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086324A1 (en) * 1999-05-14 2002-07-04 Laird Peter W. Process for high throughput DNA methylation analysis
CN106947830A (zh) * 2017-05-16 2017-07-14 中山大学肿瘤防治中心 用于诊断、预测肝癌疗效和预后的基因甲基化面板

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476013B2 (en) * 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
CN106232833A (zh) * 2014-01-30 2016-12-14 加利福尼亚大学董事会 用于非侵入性诊断的甲基化单体型分析(monod)
MA39951A (fr) * 2014-05-09 2017-03-15 Lifecodexx Ag Détection de l'adn provenant d'un type spécifique de cellule et méthodes associées
CN104745575B (zh) * 2014-08-08 2019-03-12 博诚研究中心 用于检测细胞增殖性异常或疾病程度分级的基因组合物及其用途
EP3452620A4 (en) * 2016-05-04 2020-01-01 Queen's University At Kingston CELL-FREE DETECTION OF METHYLATED TUMOR DNA
CN107727865A (zh) * 2016-08-11 2018-02-23 博尔诚（北京）科技有限公司 肿瘤标志物的系统性检测方法及其应用
CN110379465A (zh) * 2019-07-19 2019-10-25 元码基因科技（北京）股份有限公司 基于rna靶向测序和机器学习的癌症组织溯源方法
CN110499364A (zh) * 2019-07-30 2019-11-26 北京凯昂医学诊断技术有限公司 一种用于检测扩展型遗传病全外显子的探针组及其试剂盒和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086324A1 (en) * 1999-05-14 2002-07-04 Laird Peter W. Process for high throughput DNA methylation analysis
CN106947830A (zh) * 2017-05-16 2017-07-14 中山大学肿瘤防治中心 用于诊断、预测肝癌疗效和预后的基因甲基化面板

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENG JINMING: "Integrative Analysis of DNA Methylation and Gene Expression Reveals Hepatocellular Carcinoma-specific Diagnostic Biomarkers", CHINESE MASTER’S THESES FULL-TEXT DATABASE, MEDICINE & HEALTH SCIENCES, 15 January 2020 (2020-01-15), XP055842144 *
HLADY RYAN A., ZHAO XIA, PAN XIAOYU, YANG JU DONG, AHMED FOWSIYO, ANTWI SAMUEL O., GIAMA NASRA H., PATEL TUSHAR, ROBERTS LEWIS R.,: "Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA", THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 9, no. 24, 1 January 2019 (2019-01-01), AU, pages 7239 - 7250, XP055842150, ISSN: 1838-7640, DOI: 10.7150/thno.35573 *
KUO I-YING, JEN JAYU, HSU LIEN-HUEI, HSU HAN-SHUI, LAI WU-WEI, WANG YI-CHING: "A prognostic predictor panel with DNA methylation biomarkers for early-stage lung adenocarcinoma in Asian and Caucasian populations", JOURNAL OF BIOMEDICAL SCIENCE, vol. 23, no. 1, 1 December 2016 (2016-12-01), XP055842148, DOI: 10.1186/s12929-016-0276-x *

Also Published As

Publication number Publication date
CN112662761A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
WO2021169875A1 (zh) 一种癌症基因甲基化检测系统和在该系统在中执行的癌症体外检测方法
WO2021180106A1 (zh) 一种检测消化道5种肿瘤的探针组合物
WO2021128519A1 (zh) Dna甲基化生物标志物组合、检测方法和试剂盒
WO2021180105A1 (zh) 一种检测常见两性癌症的探针组合物
WO2021185274A1 (zh) 一种检测6种中国高发癌症的探针组合物
EP2891720B1 (en) Method for screening cancer
KR20100058449A (ko) 종양 특이적 ｄｎａ 서열의 특이적 증폭
WO2022143396A1 (zh) 乳腺肿瘤特异性甲基化检测的试剂盒
WO2021175284A1 (zh) 检测3种实质性器官肿瘤的探针组合物
WO2021169874A1 (zh) 一种检测3种管腔性器官肿瘤的探针组合物
CN107630093B (zh) 用于诊断肝癌的试剂、试剂盒、检测方法及用途
CN114182022A (zh) 一种基于cfDNA碱基突变频率分布检测肝癌特异突变的方法
CN106947805A (zh) 基于ARMS‑PCR法检测人外周血游离DNA中septin9基因甲基化的荧光PCR方法、试剂盒及体系
WO2021185275A1 (zh) 一种检测11种癌症的探针组合物
CN111826446A (zh) 用于膀胱癌早期筛查与辅助诊断的引物、探针和试剂盒
US11535897B2 (en) Composite epigenetic biomarkers for accurate screening, diagnosis and prognosis of colorectal cancer
EP2450455B1 (en) Method for determining presence or absence of epithelial cancer-origin cell in biological sample, and kit therefor
CN114507734B (zh) 用于甲状腺癌筛查的标志物、探针组合物及其应用
CN114540497B (zh) 用于膀胱癌筛查的标志物、探针组合物及其应用
CN114703281B (zh) 用于睾丸癌筛查的标志物、探针组合物及其应用
WO2024001668A1 (zh) 用于检测肺结节良恶性的甲基化分子标记物及其应用
CN114369664B (zh) 用于胰腺癌筛查的标志物、探针组合物及其应用
WO2023082139A1 (zh) 一种用于诊断肝癌的核酸及蛋白检测试剂盒
WO2023082140A1 (zh) 一种用于诊断肝癌的核酸检测试剂盒
WO2024031860A1 (zh) 一种用于结直肠癌诊断的多基因dna甲基化联合检测试剂盒及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21763743

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21763743

Country of ref document: EP

Kind code of ref document: A1